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Abstract

OVEL MECHAISMS I ASTROCYTE GEE REGULAYIO AD
FUCTIO
By Sandeep Kumar Singh, M.Sc.
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Tomasz Kordula, Ph.D.
Associate Professor, Department of Biochemistry and Molecular Biology

This dissertation sheds light on several novel mechanistic findings in astrocyte
specific gene regulation and function by the NFI-X transcription factor which can be
further extrapolated to astrocyte differentiation and glial tumor invasion. First, we cloned
and analyzed human NFI-X3, a novel splice variant of the nfix gene, which contains a
unique transcriptional activation (TA) domain completely conserved in primates. In
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xvii
contrast to previously cloned NFI-X1, overexpression of NFI-X3 potently activates NFI
reporters, including GFAP reporter, in astrocytes and glioma cells. The expression of
NFI-X3 is dramatically upregulated during the differentiation of neural progenitors to
astrocytes and precedes the expression of astrocyte markers such as GFAP and
SPARCL1. Overexpression of NFI-X3 dramatically upregulates GFAP and SPARCL1
expression in glioma cells, while the knockdown of NFI-X3 diminishes the expression of
both GFAP and SPARCL1 in astrocytes. Although activation of astrocyte-specific genes
involves DNA demethylation and subsequent increase of histone acetylation, the TA
domain of NFI-X3 activates GFAP expression by inducing alteration in the +1
nucleosome architecture that lead to the increased recruitment of RNA polymerase II.
Thus, we propose that NFI-X3 is the major isoform of NFI-X regulating astrocyte
specific gene expression during their differentiation, likely via nucleosomal remodeling
of the astrocyte specific promoters.
NFI-X knock-out animals display severe neuroanatomical defects including
partial agenesis of the corpus callosum and hydrocephalus, however the target genes of
NFI-X in the CNS remained elusive. Here, we show for the first time that YKL-40 is a
novel target gene of NFI-X in astrocytes and controls their migration. In addition, we
report that YKL-40 expression is activated during mouse brain development and also
during the differentiation of neural progenitors into astrocytes in vitro. In primary
astrocytes, YKL-40 expression is controlled by nuclear factor I-X (NFI-X) and signal
transducer and activator of transcription 3 (STAT3), which are known to regulate
gliogenesis. Indeed, knock-down of NFI-X and STAT3 significantly reduced YKL-40
expression in astrocytes, while overexpression of NFI-X3 (a splice isoform of NFI-X)
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dramatically induced YKL-40 expression in glioma cells. In addition, activation of
STAT3 by oncostatin M induced YKL-40 expression in astrocytes. Interestingly, STAT3
activated YKL-40 expression via its binding site located in the YKL-40 proximal
promoter, whereas direct NFI-X binding had not been detected. Surprisingly, NFI-X and
STAT3 physically interact and this complex likely regulates YKL-40 expression in
astrocytes. We further show that NFI-X controls migration and invasion of astrocytes and
glioma cells, respectively, by regulating YKL-40 expression. These novel data suggest
that YKL-40 is expressed by astrocytes during brain development and controls astrocyte
migration.
Since YKL-40 is used as a shared biomarker for ongoing inflammation and
oncogenic transformation and its (high) levels correlate to the severity of disease, we
have tested its expression in astrocytes and microglia (CNS macrophage) after treatment
of various neuro-inflammatory cytokines. Here we report, that IL-1 and IL-6/OSM
synergistically activate YKL-40 expression in astrocytes but not in microglia when added
together. Furthermore, induced YKL-40 expression can be detected in the media from
astrocytes but not from microglia. Since YKL-40 is a secreted molecule and is highly
upregulated in CSF of multiple sclerosis patients, we have tested its role in
oligodendrocyte differentiation. Preliminary observations clearly demonstrate that YKL40 inhibits myelin basic protein (MBP) expression during the in-vitro differentiation of
oligodendrocyte progenitor cells into myelin producing oligodendrocytes. Thus, we
propose that YKL-40 is produced and secreted by reactive astrocytes during various CNS
pathologies, and may inhibit MBP expression in MS.
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In summary, these studies have identified novel mechanisms in astrocyte gene
regulation and functions, and provided new insights into astrocyte biology, with the
implications for further understanding of the development and progression of CNS
pathology.
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CHAPTER 1
I TRODUCTIO
1.1 Astrocytes
Astrocytes are the ‘star’ shaped cells in the central nervous system (CNS). These
are the major sub-type of glial cells, and comprise more than 50 percent of the total
human brain cells. Evolutionarily, their morphology is conserved, suggesting their basic
functions remain conserved as well. However, astrocytes in the human cerebral cortex are
structurally much more complex than those of other mammals, and are believed to be
taking part in the learning and memory processing of the organism [1].
On the basis of morphology, antigenic phenotype and location, astrocytes can be
categorized in two main types: Protoplasmic astrocytes, and Fibrous astrocytes.
Protoplasmic astrocytes are found in grey matter and have many fine branched processes
whose end termini ensheath synapses, the cell body of the neuron as well as blood vessels
[2]. In contrast, fibrous astrocytes are mainly found in white matter and have long and
thin unbranched processes, which closely associate with nodes of Ranvier (axons) and
blood vessels. In addition, there are some specialized astrocytes namely Muller glia found
in the retina, and Bergmann glia found in the cerebellum. Based on their location and
antigenicity, these special glia can be considered as protoplasmic glia [1].
These cells were considered to be the space filling cells in the CNS with
supportive functions to their excitable neighbors, the neurons. Closely spaced to neurons
and with tight association to the endothelial cells of blood brain barrier, astrocytes
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provide energy and substrates to neurons in a neuronal activity dependent manner. Thus,
they can sense the active neurotransmission at the synapses and consequently dilate the
blood brain barrier to allow the entry of more oxygen and glucose in the active brain
region. During early brain development, astrocytes secrete factors that are critical for
active synapse formation and also synapse elimination [2]. Astrocyte-secreted cholesterol
strongly enhances the presynaptic functions; however, yet unidentified molecule(s)
enhance postsynaptic function and astrocyte secreted thrombospondin (TSP) proteins
induce retinal ganglion neurons to form synapses [3],[4]. Astrocytes can participate in
synapse elimination by activating neurons and microglia to express and secret C1q
complement [5].
During embryonic brain development, radial glia (early astrocytes) acts as stem
cells which can differentiate into neurons and oligodendrocytes [6, 7]. In addition, these
radial glia cells provide a scaffold for proper neuronal migration and hence their
appropriate location in the cerebral cortical region [8]. In addition, a subset of astrocytes
in the subventricular zone (SVZ) give rise to olfactory neurons in vivo and are capable of
forming clonal self-renewing mutipotent neurospheres [9]. Astrocytes secrete many
developmentally-regulated tropic and trophic factors which support and help guide axons
during early postnatal brain development. Interestingly, the expression of these factors is
induced in reactive astrogliosis during/post injury or in pathological states of brain and
thus are thought to help guide axon regeneration and reconnection [2] .
Thus, there is no doubt that astrocytes, the most abundant cell type in the CNS,
control many functions in the normal as well as pathological states of brain.
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1.2 Astrocytes in brain pathologies
Astrocytes are involved in almost all kinds of CNS pathologies. The most
prominent feature of astrocytes associated with CNS insult/disease is the changes in their
morphology, also known as reactive gliosis or astrogliosis, with complex, hypertrophic
and extended processes. Reactive-gliosis mainly results from the activation of astrocytes
by inflammatory cytokines released at the site of injury, infection or disease primarily by
microglia, the immune cells of the CNS [10, 11].
The dystrophic astrocytes/reactive astrocytes appear prior to the appearance of
neuritic plaque, the most prominent feature of Alzheimer’s disease (AD) and also
coincides with the distorted synaptic structures observed in mouse models of AD. This
led us to speculate that astrocytes might play a direct critical role in AD progression. In
accordance, application of anti-inflammatory drugs delays the AD progression [11].
However, all these observations are primarily associative and do not conclude the direct
involvement of astrocytes in CNS pathologies.
Direct involvement of astrocytes in disease progression can be attributed to the
dominantly inherited/sporadic forms of various neurodegenerative disorders including,
amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), RETT syndrome and the
familial form of Parkinson`s disease (PD). In the case of inherited ALS, an adult motor
neuron disease, the loss of motor neurons is associated with missense mutations in the
superoxide dismutase 1 (SOD1) gene. Interestingly, wild-type primary neurons when cocultured with the primary astrocytes from SOD1 mutant animals undergo cell death over
a 2 week period of time. This neurotoxic effect from astrocytes is coming from the
conditioned media of mutant astrocytes clearly demonstrating a direct role of astrocytes
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in ALS progression [11, 12]. However, the identity of these neurotoxic soluble factors
remains to be explored.
RETT syndrome, a neurodevelopmental disorder, is caused due to the mutations
in the gene methyl C binding protein 2 (MeCP2) located on the X- chromosome. Until
recently, MeCP2 protein was believed to be expressed exclusively in neurons in the CNS
and thus the disease was also thought to be exclusively neuronal. However, recently two
groups have elegantly shown that MeCP2 is expressed in the glial cells also particularly
in the astrocytes [13, 14]. In addition, they also demonstrated that normal neuronal
cultures when grown in the conditioned media of mutant MeCP2 astrocytes have
abnormal dendritic arbor with shorter and less number of branches, suggesting that
astrocytes also contribute to the RETT syndrome progression at least in-part [13, 14]. The
secretory/soluble factors from the mutant astrocytes remain to be identified.
Similarly, familial form of PD is associated with the mutation in the gene NURR1
which leads to low expression of Nurr1 protein, an orphan nuclear receptor. The
mechanism of Nurr1 action in PD progression has recently been demonstrated by
Michael Glass` group. This study shows that Nurr1 protein interferes with the
transcriptional activity of NF-κB and represses NF-κB induced inflammation-associated
neurotoxic factor expression. Furthermore, the inhibitory role of Nurr1 was only
observed in astrocytes and microglial cells but not in neurons [15]. Thus in the absence of
Nurr1 (as in the case of PD), microglia and astrocytes secrete soluble factors which are
neurotoxic to neurons.
Apart from the neurodegenerative disorders, some of the brain tumors known as
astroglioma (glioma) are known to be of astrocytic origin and express the astroglial
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marker gene GFAP. It is believed that, due to the oncogenic mutations, glioma cells exit
the normal astrocytic differentiation process and gain the potential of unlimited cell
division. In short astrocytes can be considered as the source of glioma [16].
Taken together from all the above examples it is clear that astrocytes actively and
directly play roles in the progression of many neurological disorders. Thus astrocytes are
now considered as novel cellular drug targets for therapeutic intervention of much
neurological pathology. However, the identity of the soluble factors released by
astrocytes and their precise mechanism of action in pathological states remains an open
area of active research.

1.3 Differentiation of astrocytes
The mammalian CNS is developed from the epithelial layer of the embryo named
as neuro-epithelium, which comprises of mutipotent neural precursor cells (NPC). These
NPCs generate neurons first (neurogenesis) from E12-E18, and glia second (gliogenesis).
During the gliogenic phase, astrocytes are generated at around E18, with their numbers
peaking in the neonatal period; oligodendrocytes are first seen postnataly. The data
accumulated over the last decade or so suggest that several signaling pathways, including
JAK-STAT pathway, SMADS, the Notch signaling and the Nuclear Factor-I (NFI)
family of transcription factors, are crutial for astrocyte differentiation and hence the
expression of astrocyte marker genes, including GFAP, SPARCL-1, GLAST, and S100B
[17, 18]. In addition, epigenetic mechanisms also control gliogenesis as evidenced by the
studies that during the early neurogenic phase most of the astrocyte-specific gene
promoters are highly methylated and hence are repressed [47].
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The pregenerated neurons from the NPCs are the prime suspects to induce
astrocyte differentiation from the same NPCs, at the late gestation period. Accordingly,
neuronal derived Cardiotrophin-1 (CT-1), an IL-6 cytokine family member that activates
the gp130-JAK-STAT pathway, directs NPCs to differentiate into astrocytes at around
day E13.5. During the same period, astrocyte-specific gene promoters are demethylated
allowing STAT3 to bind to and activate the respective gene promoters [19]. In addition,
the JAK-STAT pathway activates BMP-2 production and subsequent SMAD1 activation
followed by its translocation into the nucleus. The activated SMAD1 then forms a
complex with STAT3 bridged by p300/CBP co-activator [20] [25]. This complex binds to
the promoters of glial specific genes such as GFAP to synergistically activate their
transcription.
Recently, another group of transcription factors called the Nuclear factor-I (NFI)
family has been reported to be necessary and sufficient for gliogenesis, as shown by the
fact that the mis-expression of NFI-A factor leads to precocious expression of GLAST
and GFAP genes in chick embryonic spinal cord [18]. In agreement, NFI-A and NFI-B
knock out mice have severe brain defects including agenesis of corpus callosum, reduced
number of GFAP positive astrocytes, and loss of midline-glial population [21, 22].
Recently, our lab has demonstrated that NFI-C and NFI-X factors are critical for late
astrocyte marker gene expression in an in vitro model of astrocyte differentiation from
human neural progenitors (NPs) [23]. It was also shown that NFI factors can inhibit
neurogenesis indirectly by controlling the expression of the notch effector Hes5. Thus
NFI factors can regulate the switch from neurogenesis to gliogenesis during the mid to
late gestation period [18].
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Notch signaling which leads to the activation of transcription factor RBP-Jκ has
also been implicated in gliogenesis; however this requires an active JAK-STAT pathway.
Upon activation, notch signaling converts the RBP-Jk repressor complex into an activator
complex. The RBP-Jk activator complex binds to notch effector gene promoters
including Hes and Hesr (hes related proteins) which antagonizes proneural gene
expression [24]. However, until recently it was not known how Notch, NFI, and JAKSTAT factors precisely activate neurogenic to gliogenic switch. Elegant studies from
Kinichi Nakashima`s group has recently shown that during the development of midgestational telencephalon, Notch ligands are expressed on the committed neuronal
precursors and young neurons and that the neighboring Notch-activated NPCs achieve
the potential to differentiate into astrocytes [25]. More precisely, activation of Notch in
NPCs induces the expression of NFI-A factor, which binds to astrocyte-specific gene
promoters, leading to demethylation of astrocyte-specific genes, and subsequent derepression [25].
These studies, mainly from mouse brain development, have greatly increased our
understanding of astrocyte differentiation process; however, the precise regulation and
role of NFI factors in this process is still unclear.

1.4 uclear Factor I
The phylogenetically conserved NFI family of transcription factors regulates the
expression of various cellular and viral genes, together with adenoviral DNA replication.
It comprises of four DNA-binding proteins: NFI-A, NFI-B, NFI-C, and NFI-X [26].
During mouse embryogenesis, they are expressed in complex, unique and overlapping
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patterns. Their expression is developmentally regulated [27], suggesting that they may
play distinct and important roles in tissue specific gene expression during mammalian
embryogenesis.
All four NFI isoforms are expressed in many tissues, with high levels of expression of
NFI-A, NFI-B, and NFI-X transcripts in the developing neocortex [27]. Approximately,
75,000 NFI binding sites are found in the human genome in-silico [26]; however only a
few NFI binding sites have been characterized for cell or tissue specific genes, these
include; astrocyte specific GFAP (Glial Fibrillary Acidic Protein), S100B [28, 29], radial
glial specific B-FABP (Brain Fatty Acid Binding Protein) [30], and oligodendrocyte
specific MBP (myelin basic protein) [31]. NFI binding sites have also been characterized
for ubiquitously expressed genes, including p21WAF1/CIP1, tumor suppressor p53, and
cyclin D1. Therefore, NFI proteins seem to be not only involved in development, but also
in cellular differentiation and cell growth.
Indeed, knockout studies have validated a functional role of NFI-A, NFI-B, and NFIX in the brain. Disruption of Nfia or Nfib causes late gestation neuroanatomical defects,
including agenesis of corpus callosum, size reduction in other forebrain commissures,
and loss of midline glial populations [21]. In addition, Nfib-deficient mice show aberrant
hippocampus and pons formation, and defects in lung development [32], while Nfixdeficient mice show severe skeletal defects with kyphosis, and brain defects, including
hydrocephalus and ventricle enlargement [33]. In contrast, the disruption of Nfic results
in early postnatal defects in tooth formation [34]
NFI factors share a highly homologous, conserved 200-aa N-terminal DNAbinding/dimerization domain that is also sufficient for adenoviral DNA replication in
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vitro. NFIs can form homo or heterodimers and binds to the consensus DNA sequence
TTGGC (N) 5GCCAA with almost equal efficiency. However, C-terminal transcriptional
regulation domains of NFIs significantly differ with each other across species. In fact,
frequent alternative splicing can create as many as nine protein products for each gene
[26]. In addition, differential phosphorylation of NFIs in various cell types provide an
extra layer of regulation of transcriptional activity [35].
The NFI proteins have been implicated in both transcriptional activation and
transcriptional repression, which are cell-, tissue-, and promoter- type specific. A number
of different mechanisms are proposed to explain NFIs transcriptional activity. NFI-C was
shown to activate transcription by its C-terminal proline rich transactivation domain
through direct interaction with the basal transcription machinery. Infact, the proline rich
domain of NFI-C contains a heptapeptide which is highly homologous to the C-terminal
domain (CTD) of RNA-polymerase II [36]. In addition, deletion of the CTD like domain
in NFI-C abolishes its interaction with human TFIIB [37] and yeast TBP [38], and hence
transactivation. According to another proposed mechanism, NFI can activate gene
transcription by simply removing the repressive histone H1 from the gene promoter [39].
In addition, the C-terminal proline rich domain of NFI-C has been shown to directly
interact with histone H3 [26], and bind to co-activator proteins, including p300/CBP and
Ski [26]. These data suggest that NFI-C can activate gene transcription by the
simultaneous removal of the repressive histone H1 and by bringing the co-activator
complexed with histone H3. The transcriptional repression of NFI includes activities such
as competition between NFI and more potent trans-activators for binding at adjacent or
overlapping sites. Competition between NFI and Sp1 has been proposed to repress the
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Sp1 activation of the mouse α1 (I) collagen promoter [40]. Moreover, the C-terminal
transcription activation domain can bring repression in a cell-, promoter- type manner
[41]. However, the splice isoforms of NFI-X present in CNS cells and their role during
gliogenesis are not known.

1.5 Gliomagenesis
Gliomas are one of the most common primary brain tumors [42]. According to
W.H.O. criteria, gliomas can be divided into four grades based on their histological
appearances; pilocytic astrocytoma, grade I; diffuse astrocytoma, grade II; anaplastic
astrocytoma, grade III; and glioblastoma multiforme, grade IV [43]. Of these Grade III
and grade IV tumors, also known as malignant gliomas, are the most aggressive [43].
Despite the common treatment procedures used for GBM, including surgery, radiationtherapy, and chemotherapy, there is a poor prognosis for survival with a median patient
survival between 9-12 months mainly due to their invasive nature.
Gliomas harbor a number of mutations in specific cellular transduction pathways
including mutations in the p53 tumor suppressor activation pathway, EGFR/Ras
activations, and PTEN mutation affecting PI3K-AKT pathway [43]. However, the exact
cell of origin that leads to formation of gliomas is not known. Recent advances in brain
tumor biology has identified stem like cells in gliomas thus supporting the notion that the
bulk of the malignant cells in brain cancers are generated by relatively rare fractions of
self renewing, multipotent, brain tumor initiating cells [44, 45]. These BTSCs express
CD133 and nestin, which are the markers of NPCs [44]. In addition, BTSCs, similar to
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NPCs, are radioresisatant [46], chemoresistant, and express higher levels of ABC
transporters [47, 48] compared to their autologus CD133- cells. In addition, it is known
that glioma or tumor cells can utilize some of the normal functions of astrocytes in a
deregulated way. It is apparent that understanding of the normal astrocytic differentiation
process could lead to the better knowledge of understanding of gliomagenesis and
perhaps novel therapeutic implementation to kill glioma cells specifically.

1.6 IL-6 cytokine family and the JAK-STAT pathway
Interleukin-6 (IL-6) family of cytokines including OSM, CNTF, LIF, and CT-1 is
a group of potent, pleiotropic, inflammatory factors that mediates a number of redundant
biological functions including cell survival, proliferation, migration, apoptosis, and
development and differentiation [49]. Like other cytokines, this group facilitates its
functions by binding to and heterodimerizing its receptors. Upon ligand binding the
individual

specific

receptor

subunit

IL-6Rβ,

LIFRβ,

CNTFRβ,

or

OSMRβ

heterodimerizes with a common gp130 receptor subunit. This leads to the activation of
Janus kinases (Jak1, Jak2, Jak3 and Tyk2), the receptor associated tyrosine kinases,
which phosphorylates tyrosine residue within the cytoplasmic domain of gp130 subunit
and thus creating a docking site for Src-homology-2 domain containing proteins,
including STATs. In the active receptor complex, STAT proteins are tyrosine
phosphorylated which leads to their dimerization and subsequent translocation into the
nucleus where it recognizes specific DNA elements in the promoter regions of target
genes to activate transcription [49]. STATs can also be activated by many receptors with
intrinsic receptor tyrosine kinase (RTKs) activity including EGF, and PDGF and non11

RTKs, such as SRC [50-52]. There are seven known STAT proteins: STAT1, STAT2,
STAT3, STAT4, STAT5a, STAT5b, and STAT6 [53]. Depending on the ligand type and
the strength of its stimulus STATs can form homo/heterodimers. All except STAT2 can
form homodimers. In-addition STAT1 and STAT2, and STAT1 and STAT3 can form
heterodimers, and several STATs can form tetramers or even higher order structures [53,
54]. Like other transcription factors, STATs too have a DNA binding, a dimerization and
a transcriptional activation domain. Various post-translational modifications including
acetylation, phosphorylation, sumoylation, and ubiquitination also have been shown to
regulate its transcriptional activity and biological response. Particularly, serine 727
phosphorylation within the transactivation domain of STAT1 and STAT3 enhances their
transcriptional activity without affecting their DNA binding properties. Nuclear export of
STAT proteins is favored once the phosphorylation mark is removed by nuclear
phosphatases, such as TC45 in the case of STAT1 and STAT3 [55].
In agreement with its role in regulating a plethora of physiological functions,
JAK-STAT signaling is under tight control of negative regulation at different levels.
There are several cytoplasmic tyrosine phosphatases including SH2-containing
phosphatases 1 (SHP-1), SHP-2 and protein tyrosine phosphatases 1B (PTP1B) that
dephosphorylate receptor and kinase phosphorylation sites thus disabling the recruitment
of SH2 domain containing proteins including STATs [56, 57]. Another group of
cytoplasmic inhibitors are the suppressors of cytokine signaling (SOCS) proteins, which
bind to the receptor sites and/or Jak catalytic sites to block further STAT activation.
These cytokine induced molecules can also drive protein turn over of the receptor and
associated molecules by ubiquitin-proteasome mediated degradation [58]. In addition,
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there are a few negative regulators of JAK-STAT signaling within the nucleus, such as
protein inhibitors of activated stats 1 (PIAS1) and PIAS3. PIAS1 and PIAS3 interacts
with tyrosine phosphorylated STAT1 and STAT3, respectively, and block their DNA
binding in vitro [53].

1.7 IL-1 cytokine and its downstream signaling
Interleukin-1 (IL-1) is the predominant pro-inflammatory cytokine associated
with the host-defense response to injury and infection [59]. It is an important mediator of
both acute and chronic CNS disorders including brain trauma, stroke, epilepsy, AD and
PD [60] [11]. The most characterized isoforms of IL-1 are IL-1α and IL-1β. Both of them
act as agonists and binds to the same type I receptor (IL-1R1), which then associates with
an accessory protein (IL-1R1AcP) to activate the downstream signaling cascades [61,
62]. Furthermore, this signaling leads to the production of secondary inflammatory
mediators such as cytokines, chemokines and prostaglandins. There is a naturally
occurring IL-1R antagonist (IL-1Ra) , which is soluble in nature and competes with IL1R as well as acts as a buffering agent for the excess of IL-1 to inhibit downstream
signaling [59, 62, 63].
The level of IL-1 expression in normal healthy individuals is very low. However,
its expression dramatically increases in reply to the injury/infection [59]. In CNS
activated microglia are the major contributor for IL-1 production. Soluble factors released
by activated microglia then can stimulate astrocytes, oligodendrocytes and even neurons
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for the further production of IL-1 [11, 64-66]. All the cell types of the CNS except
microglia express IL-1R1 and therefore respond to IL-1 [59].
Upon binding to its receptor, IL-1 can activate various signaling cascades, mainly
the activation of the IKK-NFκB pathway and the mitogen-activated protein kinases
(MAPKs) p38 MAPK, JNK and ERK1/2 in astrocytes [67]. This activation is followed
by increased cell proliferation and hypertrophic changes in morphology also known as
reactive astrogliosis. In addition, IL-1 activated astrocytes produce VEGF and many
other factors important for angiogenesis, vessel plasticity and astrocyte migration which
are critical for recovery and repair of injury site within the brain [68]. Oligodendrocytes
can also respond to IL-1 treatment. However, IL-1 does not induce their proliferation
rather it promotes oligodendrocyte differentiation and maturation, indicating that it might
affect the re-myelination and repair process after injury [59, 69].
In neurons, low levels of IL-1 expression are considered to regulate normal
physiological functions including sleep, memory and long term potentiation. Effect of IL1 on neurons depends on the IL-1 concentration and the duration of the activation. In
neurons, IL-1 does not signal through MAPK, JNK and ERK1/2 activation; rather, it
activates Src kinase [70, 71]. Furthermore, the low concentration of IL-1 makes neurons
more vulnerable to neurotoxic effects from glial cells. Both glia and neurons produce
various neuro-trophic and growth factors in response to high concentrations of IL-1 that
promote neuronal survival [72]. At the molecular level, a high concentration of IL-1
activates the c-Rel subunit of NF-κB instead of Rel-A and, hence, is responsible for its
protective effects [73].
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In vivo, deletion of IL-1α/β gene in mice greatly reduces ischemic brain injury. In
contrast, deletion of IL-1Ra (the antagonist) increases ischemic brain injury by 3 fold and
causes increased mortality [62].
Clearly, IL-1 plays a profound role in response to CNS injury/infection. It is
intriguing that it can have neurotoxic as well as neuroprotective effects depending on its
concentration and the duration of its presence in the injured area. It will be interesting to
explore the genes/factors responsible for its contradicting role on neurons.

1.8 C S inflammation
Until recently, the CNS was considered to be an ‘immune privileged’ organ, and
to be not susceptible to inflammation. The immune cells constantly flowing in the blood
stream and surveying the injury, infection or a disease state in the various organs/ tissues
have limited access to the CNS due to the tight and impermeable nature of the blood
brain barrier (BBB). However, the CNS has its own resident immune cells known as
microglia which are of hematopoietic origin and considered to be similar to macrophages.
During early embryonic brain development, precursors of microglial cells enter into the
nervous tissue before BBB is formed [74]. The microglial cells are able to sense the very
minute changes in the local environment and respond to any injury, infection or
pathological state by secreting pro-inflammatory cytokines including IL-1, TNFα, and
IL-6. Subsequently, activation of astrocytes and microglia leads to further production of
these cytokines and secondary inflammatory mediators including prostaglandins, free
radicals and complement. In turn these mediators induce expression of many chemokines
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and cell adhesion molecules which help recruit immune cells such as leukocytes through
the BBB into the CNS [62].
Almost all the CNS pathologies have an inflammatory component. The activated
immune cells can produce many factors, including BDNF, which are otherwise
exclusively produced by the CNS cells and thus establish a cross-talk with the CNS cells
during inflammation. Similarly, CNS cells, mainly reactive astrocytes, can also produce
many inflammatory mediators and cytokines which would help immune cells such as B
cells proliferate within the CNS. Thus the nature of this cross-talk between CNS cells and
immune cells during CNS inflammation is intricate [75]. The question is if the
inflammation in CNS pathologies is beneficial or harmful? Not surprisingly,
inflammatory mediators have dual roles, with deleterious effect in the acute phase and
beneficial effect in long term repair and recovery phase of the CNS pathologies. The
proinflammatory and neurotoxic factors include Th1 type cytokines, IL1, TNF, reactive
oxygen species etc. However, the anti-inflammatory and neuroprotective factors of CNS
inflammation include Th2 type cytokines, IL-1ra, sIL-1R, BDNF, GDNF, LIF etc [11,
75, 76].
Acute CNS injuries including stroke, brain trauma and epilepsy are characterized
by increased levels of expression of pro-inflammatory mediators IL-1, TNFα, IL-6 and
free radicals and are deleterious in nature. Therapeutic use of antagonists or inhibitors of
these pro-inflammatory cytokines’ administration to acute CNS injury has a beneficial
outcome with less severe pathology in animal models [62].
Chronic CNS diseases including multiple sclerosis (MS), AD, PD and
schizophrenia are also characterized by active inflammation within the pathological
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areas. Moreover, increased expression of proinflammatory cytokines including IL-1, IL-6
and TNFα is observed in these pathologies. Microarray analysis performed on
pathological brain samples from MS, AD and PD has revealed that enriched levels of
mRNA of many other inflammation associated genes, indicating an active ongoing
inflammation within these neurodegenerative diseases. The application of antiinflammatory drugs in animal models of these conditions improves disease pathology,
supporting the idea that ongoing inflammation actively participates in the chronic CNS
disease progression [62].
Presence of the reactive astrocytes is another hallmark of CNS inflammation.
They not only produce many inflammatory mediators, chemokines, and angiogenic
factors but also form a physical barrier by forming gliotic scar surrounding the inflamed
area. The gliotic scar inhibits axon regeneration during repair phase, suggesting a harmful
role for reactive astrocytes in the CNS inflammation/injury. However, when reactive
astrocytes were ablated in a transgenic animal, more neuronal cell death was observed
upon injury/insult [77]. This demonstrates that reactive astrocytes, despite acting as
physical barrier, provide neuronal support in the inflamed/injured area by producing
many neuro-trophic factors such as BDNF and GDNF. They also secret thrombospondins
which are involved in synapse formation, thus helping synapse regeneration after injury
[78].
Thus, it is quite evident that inflammation associated with CNS actively plays a
crucial role in CNS disease progression. Indeed, targeting CNS inflammation is
considered as therapy for CNS diseases. But, we have to be cautious of the fact that
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inflammation has dual role to play in CNS pathologies. Therefore the identities of the
dual nature of inflammation need to be addressed in order to design new therapies.

1.9 Inflammation associated with cancer
The link between cancer and inflammation has been made by epidemiological
studies that suggest chronic inflammation predisposes individuals to many types of
cancers. It is also observed that non-steroidal anti inflammatory drugs reduce the risk of
developing certain type of cancers including colon and breast cancer and reduces the
mortality rate caused by these tumors. Inflammatory cells and inflammatory mediators
are found in almost all types of cancer microenvironment from human tumor biopsies.
Thus inflammation is associated with cancer incidence and actively promotes tumor
progression [79]. The expression of the pro-inflammatory cytokines including IL-1, IL-6,
OSM, TNFα and prostaglandins are highly upregulated in cancer associated
inflammatory cells as well as within cancer cells [80-82]. Targeting cancer associated
inflammation for drug therapeutics might synergistically act together with the
conventional drugs used for cancer therapy.
Two distinct pathways can be drawn in order to link inflammation and cancer: in
the extrinsic pathway, chronic inflammatory condition increases the risk of cancer
development (for e.g. inflammatory bowel disease) and in the intrinsic pathway, genetic
mutations in oncogenes causes inflammation and tumor development. Despite two
different modes of association, both pathways ultimately activate the same downstream
inflammation associated transcription factors NF-κB and STAT3 [79]. Because of the
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ability of NF-κB to induce many inflammatory mediators and to play a pivotal role in the
normal infection-driven immune response, NF-κB is regarded as the major player in
inflammation-induced

tumorigenesis

and

anti-tumor

immunity.

In

accordance,

constitutively active form of NF-κB complexes has been observed in many forms of
malignant tumors [54]. The repertoire of genes regulated by NF-κB falls in the category
of pro-survival, anti-apoptotic, angiogenic and metastatic functions, which are hallmarks
of tumor associated inflammation. Some of the factors downstream of NF-κB are IL-6,
TNFα, IL-1, and COX-2 etc which can further activate inflammation associated gene
expression in an autocrine and paracrine fashion. Apart from its role in tumor progression
NF-κB can also drive T-cell mediated anti-tumor immunity by upregulating Th1 type
cytokines such as IL-12 and interferon-γ (IFNγ) [54, 79]. It is intriguing how NF-κB
serves as a regulator of cancer promoting and cancer inhibitory gene expression at the
molecular level. The NF-κB family consists of RELA, REL, RELB, p50 and p52
members. Among these only RELA, REL and RELB possesses a transcriptional
activation domain. The RELA-p50 heterodimer is the most general NF-κB transcription
factor, which is critical for expression of pro-inflammatory genes including IL-1, IL-6,
IL-23 and COX2 which can also serve as cancer promoting factors. In contrast, the RELp50 heterodimer mainly activates gene expression of T helper type 1 (Th1) cytokines
such as IL-12 and IFNγ. It is also noteworthy that, within the tumor cells, only RELA but
not REL is constitutively activated implying that somehow cancer cells utilize procarcinogenic functions and at the same time escape the anti-tumor immunity posed by
NF-κB activation.
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The family of STAT transcription factors controls immune responses within the
tumor microenvironment. Particularly STAT1 activation leads to production of IL-12
which induces production of IFNγ, a Th1 type cytokine, that subsequently activate
cytolytic activity of macrophages, natural killer cells and CD8+ T cells [53]. In contrast,
constitutively activated STAT3 is the major cancer promoting and inflammation
associated transcription factor, which increases tumor cell proliferation, survival,
metastatic invasion and also suppresses anti-tumor immunity. At the same time STAT3
also mediates tumor promoting inflammation. In agreement with this, constitutively
active STAT3 is present in almost all cancer types. The major inducer of STAT3
signaling are the IL-6 type family cytokines including IL-6, LIF, OSM, IL-10 and IL-23
[54]. In addition, STAT3 can also be activated by many growth factor receptors and
associated tyrosine kinases for eg. EGFR, PDGFR, and SRC [83, 84]. All of these
tyrosine kinases have been found to be either mutated or over-expressed and hence are
constitutively active in many type of cancers leading to persistent activation of STAT3.
The genes regulated by STAT3 can be categorized into anti-apoptotic, pro-proliferative,
angiogenic, metastatic and Th17 type cytokines based on their functions. The inhibition
of anti-tumor immune response of STAT3 comes by virtue of the fact that it can interact
and thus inhibit STAT1 and NF-κB regulated Th1 type cytokine gene expression [85,
86]. The cancer promoting function of STAT3 can be rendered to its regulation of many
proinflammatory cytokines gene expression including IL-6, IL-1, MCSF, and COX-2.
These proinflammatory cytokines released by tumor cells, harboring constitutive active
STAT3, can act in a paracrine way to stimulate stromal cells in the tumor
microenvironment, thus establishing a feed forward loop between tumor cells and the
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immune cells in the microenvironment [86]. The importance of STAT3 in tumorigenesis
is strongly demonstrated by the finding that, in the absence of Stat3 alleles, carcinogens
were able to induce inflammation but not tumor incidence [87].
Given the crutial role of NF-κB and STAT3 factors in cancer-associated
inflammation, it is not surprising that both the factors can interact with each other at
multiple levels to further enhance the cancer promoting effect. In many cancers both the
factors are constitutively activated within the same cells [87]. Both factors induce the
expression of highly overlapping repertoire of proliferative, anti-apoptotic, angiogenic
and metastatic genes [79, 87]. Constitutive activation of nuclear NF-κB requires its
acetylation by p300, which itself requires STAT3. Many NF-κB activated genes
including IL-6 and IL-23 are also activator of STAT3 signaling. In contrast to the above
similarity, STAT3 opposes the anti-tumor immunity activated by NF-kB. REL-p50 NFκB complex specifically regulates Th-1 immunostimulatory genes which possesses antitumor immunomodulatory effect [49]. Persistently activated STAT3 down-regulates the
expression of REL subunit, thus diminishing its anti-tumor effect, allowing tumor to
progress [88].
Like many other tumors, STAT3 and NF-κB factors are constitutively activated in
almost all human glioblastoma multiforme (GBM) tissue, the most aggressive form of
brain tumor. Furthermore, GBMs have higher expression levels of IL-6 and OSM leading
to constant activation of STAT3 signaling [89]. The deregulation of the expression of
many growth factor receptors and their mutation can also lead to activation of STAT3
and NF-κB.
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1.10 Chitinase 3-like 1 (CHI3L1) or YKL-40
YKL-40 is a secreted 40 kDa glycoprotein. It is also known as human cartilage
glycoprotein-39 (HC gp-39), Chitinase 3-like protein-1 (CHI3L1), the mouse homologue
breast regression protein-39 (BRP-39), and chondrex. The gene for YKL-40 is located on
chromosome 1q31-q32 in human. Based on crystal structure homology YKL-40 belongs
to glycohydrolase family 18, which is comprised of many bacterial and eukaryotic
proteins with chitinase activity [90] [91]. The YKL-40 protein has 383 amino acids and is
synthesized with an 8 amino acid N-terminal pro-peptide sequence which is cleaved
before the protein gets secreted. Due to a single amino acid substitution of glutamate to
leucine in its core chitinase binding pocket, YKL-40 is an enzymatically inactive protein,
though it still binds to chitin and many other carbohydrate molecules [91].
In normal individuals the major source of YKL-40 levels are activated
macrophages, neutrophils, activated chondrocytes, synoviocytes and smooth muscle cells
[91]. It is also highly upregulated during the differentiation of monocytes to
macrophages, and smooth muscle cell differentiation [92]. However, expression of YKL40 has been found to be highly upregulated in most of the pathologies associated with
ongoing inflammation, tissue remodeling and cancers such as rheumatoid arthritis,
osteoarthritis, asthma, breast cancer cells, Glioblastomas, papilliary thyroid carcinomas,
and extraskeletal myxoid chondrosarcoma, colon cancer, melanoma and metastatic
prostrate cancer. Furthermore, a high level of YKL-40 expression is also correlated with
the disease severity and the high mortality rates of various pathological states, including
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GBM. In agreement, YKL-40 expression increases on stimulation with proinflammatory
cytokines in the macrophages and many other cell types including chondrocytes, and
cancer cells [91, 93]. Moreover, mice lacking YKL-40 gene showed impaired antigen
induced Th2 responses, with YKL-40 being a potent inhibitor of death-receptor induced
inflammatory cell apoptosis. The expression of IL-4 and IL-13 level was decreased in
YKL-40 null animals challenged with antigen compared to the sham-treated animals [94].
Despite its high level of expression in almost every pathology, regulation of its
expression and the functions of YKL-40 remain poorly defined. Analysis of the -1.3 kb
upstream region of YKL-40 promoter revealed presence of several transcription factor
binding sites including, AP-1, CEBP, Sp1, Sp3, NF-kB and ETS [92]. Moreover, during
monocyte to macrophage differentiation expression of YKL-40 is mainly controlled by
the SP-1 transcription factor [92]. In response to proinflammatory cytokines IL-1 and
TNFα, expression of YKL-40 is regulated by NF-κB transcription factor in chondrocytes
[93]. However, cell and tissue specific expression of YKL-40 can not be ruled out as, IL1 and TNFα represses YKL-40 expression in glioma cells [95]. In addition, the level of
YKL-40 expression increases upon stress stimuli including, hypoxia, cell confluence,
serum starvation, and genotoxic stress (UV irradiation) in glioma cells [96]. However,
hypoxia induced expression of YKL-40 was independent of the HIF-1 transcription factor
[96].
There have been few studies demonstrating functions of YKL-40. It can work as a
mitogenic factor for several cell types including skin and lung fibroblasts, chondrocytes
and synovial cells. It also act as a pro-survival factor when cells are exposed to stress
conditions [91]. Moreover, primary transformed astrocytes overexpressing YKL-40 are
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resistant to irradiation treatment [97]. In addition, YKL-40 can also serve as chemotactic
factor for HUVECs, and as adhesion and migration factor for vascular smooth muscle
cells. Indeed, its overexpression significantly increases migration of transformed
astrocytes [97]. Thus, in general, YKL-40 appears to function as a tissue remodeling, prosurvival, and pro-growth factor. In agreement to its pro-survival and pro-growth
functions, YKL-40 has been shown to activate MAPK/ERK1/2 and PI3K/AKT signaling
when added exogenously [98, 99]. However, the precise mechanism of this activation is
not known. Since, YKL-40 protein contains a heparan binding motif it has recently been
shown that YKL-40 can bind to syndecan-1 (receptor for heparan sulfate binding protein)
and which further enhances its association with avb3 intergrin. This complex formation
leads to the phosphorylation and activation of FAK, and subsequent activation of ERK1/2
and PI3K [98]. It is also noteworthy that most of the growth factors, including FGF,
PDGF, and EGF require syndecan proteins in order to bind to and activate their specific
receptors [100, 101]. Likewise we may speculate that YKL-40 have a specific
unidentified receptor and can function like many other growth factors. It may also
compete with the growth factor binding with syndecans. In agreement, YKL-40 has been
shown to replace bound bFGF from heparan sulfate columns, and thus could negate
functions of bFGF, as shown in hippocampal neuronal cultures [102].
Gene profiling and CSF protein profiling experiments done on patients associated
with several CNS pathological states including schizophrenia, Alzheimer’s disease,
Parkinson`s disease, multiple sclerosis, RETT syndrome, and glioblastoma have provided
evidence that expression of YKL-40 is high in CNS pathologies [97, 103, 104]. However,
the regulation and role of YKL-40 in CNS cell types remains elusive. Recently, it is
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shown that increased expression of YKL-40 is associated with the increase in CSF viral
load in SIVE. This increased YKL-40 expression was found in association with the
microglial nodules in SIVE [102]. They further demonstrated that, in vivo YKL-40
protein was deposited around astrocytes. However, in an in vitro culture only
macrophages and microglial cells but not neurons and astrocytes could produce YKL-40.
It was also shown that YKL-40 induces inhibition of axonal branching induced by bFGF
by replacing bFGF from extracellular matrix [102]. Thus it is clear that regulation of its
expression and function of YKL-40 during normal brain development as well as in
various CNS pathologies remains open for further analysis.

1.11 Hypothesis/Aim:
Since, NFI-X play critical role in normal mouse brain development, and is known
to have several splice isoforms. We hypothesize that different splice isoforms of NFI-X
might have different effects on normal astrocyte gene regulation and function.
Furthermore, glioma cells, which are thought to be derived from astrocytes, could utilize
the differential functions of NFI-X isoform regulated genes into their advantage to form
aggressive tumors.
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CHAPTER 2
THE U IQUE TRA SCRIPTIO AL ACTIVATIO
DOMAI OF THE UCLEAR FACTOR-I-X3 IS CRITICAL
TO SPECIFICALLY I DUCE MARKER GE E
EXPRESSIO I ASTROCYTYES

2.1 ABSTRACT
Transcription factors of the Nuclear Factor 1 (NFI) family regulate normal brain
development in vertebrates. However, multiple splice variants of four NFI isoforms exist,
and their biological functions have yet to be elucidated. Here, we cloned and analyzed
human NFI-X3, a novel splice variant of the nfix gene, which contains a unique
transcriptional activation (TA) domain completely conserved in primates. In contrast to
the previously cloned NFI-X1, overexpression of NFI-X3 potently activates NFI
reporters, including a GFAP reporter construct, in astrocytes and glioma cells. The GAL4
fusion protein containing the TA domain of NFI-X3 strongly activates the GAL4
reporter, while the TA domain of NFI-X1 is ineffective. The expression of NFI-X3 is
dramatically upregulated during the differentiation of neural progenitors to astrocytes and
precedes the expression of astrocyte markers such as GFAP and SPARCL1.
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Overexpression of NFI-X3 dramatically upregulates GFAP and SPARCL1 expression in
glioma cells, while the knockdown of NFI-X3 diminishes the expression of both GFAP
and SPARCL1 in astrocytes. Although the activation of astrocyte-specific genes involves
DNA demethylation and subsequent increase of histone acetylation, the TA domain of
NFI-X3 activates GFAP expression by inducing alteration in the +1 nucleosome
architecture that lead to the increased recruitment of RNA polymerase II.
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2.2 I TRODUCTIO
Astrocytes are critical for the normal functions of the brain but also play a destructive
role in many diseases of the central nervous system. Nevertheless, mechanisms
controlling their differentiation and astrocyte-specific gene expression are only partially
understood. Astrocyte differentiation is promoted by the activation of several signaling
pathways, including the JAK-STAT pathway [17, 105, 106], the activation of SMADs
[106, 107], the activation of Notch signaling [108, 109], and the activation of genes
encoding the Nuclear Factor-1 (NFI) family of transcription factors [25, 32, 35, 110-113].
During vertebrate embryonic development, neurons are generated first, followed by glia.
This neurogenic-to-gliogenic switch is induced by the activation of the JAK-STAT
signaling pathway in neural precursors by neuron-derived cardiotrophin-1 (CT-1) [17].
Specifically, STAT3 induces production of BMP-2, which subsequently activates
SMAD1 [106]. In turn, SMAD1 forms a complex with STAT3 and induces
astrogliogenesis [114]. In addition to JAK-STAT and BMP-SMAD1 pathways, Notch
signaling also affects gliogenesis by activation of RBP-Jκ transcriptional activity [20,
109], the induction of the NFI expression [25], and concomitant demethylation of the
astrocyte-specific regulatory elements [25].
The NFI family of transcription factors has recently emerged as important regulators
of gliogenesis [22, 25, 26]. These proteins, encoded by four genes highly conserved from
chickens to humans (fia, fib, fic, fix), regulate the transcription of various cellular
and viral genes, as well as viral DNA replication [26, 115]. In vertebrates, products of
these genes (NFI-A, -B, -C, and -X) share conserved N-terminal DNA binding and
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dimerization domains, followed by a subtype specific domain, and a variable C-terminal
transactivation domains [116].
In mammals, the NFI genes are expressed in overlapping patterns during
embryogenesis, with high levels of expression of NFI-A, -B, and -X in the developing
neocortex [27]. The fia and fib knockout mice are characterized by neuroanatomical
defects, including agenesis of the corpus callosum, loss of specific midline glial
populations, and a 5-10 fold decrease in the expression of glial fibrillary acidic protein
(GFAP), which is an astrocyte marker [21, 32, 113]. In addition, fib-deficient mice
present aberrant hippocampus and pons formation, and die due to the defects in lung
development [32]. The immature nestin-positive glia populate the hippocampus of fibdeficient mice, but fail to mature into GFAP-positive astrocytes [117]. In contrast,
disruption of the fic gene results in early postnatal defects in tooth formation, including
the loss of molar roots and aberrant incisor development [34]. The fix knockout mice
have recently been generated by two independent groups [118, 119], who reported
multiple effects [120]. The fix gene knockout causes postnatal lethality in most of the
animals, and leads to hydrocephalus and partial agenesis of the corpus callosum [118].
These mice also develop a deformation of the spine with kyphosis, due to a delay in
ossification of vertebral bodies and a progressive degeneration of intervertebral disks.
However, fix knockout mice survive on a soft chow diet, but are characterized by
increased brain weight, expansion of the brain along the dorsal ventricle axis, and
aberrant formation of the hippocampus [119]. The knock-out phenotypes suggest that
NFI-A, -B, and -X are important for normal brain development; however, the identity of
the affected cell type(s) is not clear. Recently, both NFI-A and -B were shown to
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regulate gliogenesis in the chick embryo, with NFI-A also controlling the maintenance of
neural precursors [18].

More recently, NFI-C and -X were shown to regulate the

expression of late astrocyte markers during the differentiation of neural precursors into
astrocytes in vitro [121].
Alternative splicing is a common mechanism of generating transcription factors with
diverse functions in the brain [122-125]. Accordingly, transcripts of all four NFI genes
are alternatively spliced, yielding many different proteins from a single gene [126, 127]
with several different splice variants of NFI-X identified in human cells [128]. Here, we
cloned and characterized a novel human NFI-X splice variant X3 (NFI-X3), which
regulates gene expression in primary human astrocytes. This splice variant contains a
unique transcriptional activation (TA) domain that is remarkably conserved in mammals,
including mice, rat, dog, macaques, and humans. Mechanistically, the TA domain of NFIX3 activates GFAP expression by inducing structural alteration at the +1 nucleosome
positioned at the GFAP transcription start site, and thus increasing PolII occupancy at this
promoter.
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2.3 MATERIALS A D METHODS
2.3.1 Cell culture. Human BG01V embryonic stem cells (ATCC, Rockville, MD) were
cultured on mitomycin C-inactivated mouse embryonic fibroblast (MEF) layer. Cells
were cultured in DMEM/F12 medium, supplemented with 20% knockout serum
replacement (Gibco, Grand Island, NY), 1 mM L-glutamine, 0.1 mM nonessential amino
acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml basic fibroblast growth factor
(bFGF) (PeproTech, Rocky Hill, NJ), and 0.1 mM β-mercaptoethanol. Cells were
propagated in 4 day cycles, and enzymatically passaged with collagenase and trypsin.
Human cortical astrocyte cultures were established using dissociated human cerebral
tissue as previously described [129]. Cortical tissue was provided by Advanced
Bioscience Resources (Alameda, CA), and the protocol for obtaining postmortem fetal
neural tissue complied with the federal guidelines for fetal research and with the
Uniformed Anatomical Gift Act. Human glioblastoma U373-MG cells and human
embryonic kidney HEK293 cells were obtained from American Type Culture Collection
(Rockville, MD) while human glioma U87, U251, D54, and T98G cells were obtained
from Dr. Jaharul Haque (Cleveland Clinic Foundation, Cleveland, OH). Cells were
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf
serum, antibiotics, sodium pyruvate, and non-essential amino acids.

2.3.2 Generation of neural progenitors. BG01V neural progenitors were generated as
described previously [121]. Briefly, cells were grown in DMEM/F12, supplemented with
15% defined FBS (Hyclone, Logan, UT), 5% KSR, 2 mM L-glutamine, 0.1 mM
nonessential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml bFGF, and
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10 ng/ml leukemia inhibitory factor (LIF) (Chemicon, Temecula, CA). Subsequently,
cells were grown for 7 days in differentiation medium composed of DMEM/F12, N2
supplement (Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml
streptomycin, and 4 ng/ml bFGF. Subsequently, the MEF layer was removed and cells
were dissociated by DPBS without calcium and magnesium, followed by collagenase and
trypsin incubation. Cells were then plated on laminin and poly-L-ornithin coated dishes,
propagated in NB27 medium consisting of neurobasal medium, B27 supplement (both
from Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml penicilin, 50 µg/ml
streptomycin, 20 ng/ml bFGF, and 10 ng/ml LIF. Cells were maintained by passaging
using trypsin.

2.3.3 Differentiation into astrocytes. To generate astrocytes, neural progenitors were
cultured on laminin and poly-L-ornithine coated dishes in DMEM, supplemented with
10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, and
nonessential amino acids for 21-24 days.
2.3.4 Down-regulation of target genes. Expression of NFI-X mRNAs was downregulated using SmartPool siRNAs (si-panNFI-X) from Dharmacon (Dharmacon, Int.,
Lafayette, CO). The NFI-X3-specific siRNAs (si-NFI-X3) was designed (Software
provided on Dharmacon’s Website) to specifically target mRNA encoded by exon 9 (5’UCCUAUG CCUGAUUCCAAAUU-3’). siRNA was transfected into astrocytes using
Dharmafect 1, according to the manufacturer’s instructions.
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2.3.5 R A isolation and quantitative PCR. Total cellular RNA was prepared by Trizol
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Subsequently, 1 µg of
total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA). GFAP, SPARCL1, NFI-X, and GAPDH mRNA levels
were measured using pre-mixed primer-probe sets, and TaqMan Universal PCR Master
Mix according to the supplier’s instructions (Applied Biosystems, Foster City, CA). The
cDNAs were diluted 10-fold (for the target genes) or 100-fold (for GAPDH), and
amplified using the ABI 7900HT cycler. Gene expression levels were normalized to
GAPDH mRNA levels, and presented as a fold induction with mean values +/- standard
deviation. Statistical analysis was performed by one-way analysis of variance.
Differences were considered statistically significant when p-values were <0.05. The
expression of NFI-X3 splice isoform was analyzed using the Power SYBRGreen PCR kit
(Applied Biosystems, Foster City, CA) and the following primers: 5’-GTCGCTCGAGT
CAGAGGAACCAGGACTG-3’ and 5’-GGTAGCGGCCAGGGCAAAG-3’ (the exon 9
specific primer).

2.3.6 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2
mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany). Samples were
resolved using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher
& Schuell, Keene, NH). The anti-NFI, anti-GFAP, and anti-β-tubulin antibodies were
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), while anti-SPARCL1 antibodies
were purchased from R&D Systems (Minneapolis, MN). Antigen-antibody complexes
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were visualized by enhanced chemiluminescence using Immobilon Western blotting kit
(Millipore, Temecula, CA).

2.3.7 Synthetic oligonucleotides. The following oligonucleotides were synthesized to
amplify

the

NFI-X1

from

the

astrocyte

CGGAAGCTTCGCCATGTACTCCCCGTACTGCC-3’

cDNA:
and

5’5’-

TGTGCTCGAGTCAGAAAGTTGCCGTCCCG-3’. The NFI-X3 was amplified in two
steps to avoid the amplification of NFI-X1, which is the major splice isoform. The Nterminal

part

of

NFI-X3

was

amplified

with

the

following

primers:

5’-

GTGAAGCTTCGCCATGGATGAGTTCCACCCGTTC-3’ and 5’-GGTGATGGAGGA
GTCAAG-3’, while the C-terminus was amplified with 5’-GGTGCGGCCAGGGCAAA
G-3’ and 5’-GTCGCTCGAGTCAGAGGAACCAGGACTG-3’.

Subsequently, both

PCR products were combined, and the full length NFI-X3 was amplified with the primers
containing the HindIII and XhoI sites (underlined above). The transactivation domains of
NFI-X1 and NFI-X3 were amplified using the following primers: 5’-AGGGGATCCTG
AAGGAGTTTGTGCAGTTT-3’ and 5’-GTGTCTAGATCAGAAAGTTGCCGTC-3’
(X1TD) and 5’-AGGGGATCCTGAAGGAGTTTGTGCAGTTT-3’ and 5’-TCGTCTAG
ATCAGAGGAACCAGGACTGAG-3’ (X3TD). To generate plasmids expressing NFIX1-FLAG and NFI-X3-FLAG the following reverse primers were used: 5’-TACCAGAT
CTGAAAGTTGCCGTCCCGGGGTC-3’ and 5’-TACCAGATCTGAGGACCAGGAC
TGAGAC-3’
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2.3.8 Bisulfite sequencing. 250 ng genomic DNA were converted using EZ DNA
methylation kit (Zymo Research, Orange, CA) according to the supplier’s instructions.
Subsequently, PCR products were amplified using a pair of primers: 5’TGTAAGTAGATTTGGTAGT

ATTGGGTTGG-3’

and

5’-

CCCTTTCCTAAACACAAACTAAATAAAACC-3’. PCR products were cloned into
pCR2.1 (Invitrogen, Carlsbad, CA) and five clones were sequenced for each PCR
product.

2.3.9 Plasmids.

Reporter plasmids p10x(NFI)CAT and pGFAP(-1745)CAT were

described previously [130]. The p21(-2400)Luc reporter was provided by Dr. Bert
Vogelstein (Baltimore, MD) [131]. The p5xGAL4-Luc reporter and pCGal4 plasmid
(pCDNA3.1 containing Gal4 DNA-binding domain) were gifts of Dr. Joseph Fontes
(Kansas City, KS) [132, 133]. The PCR products containing full-length NFI-X1 and NFIX3 were digested with HindIII and XhoI, and cloned into the HindIII/XhoI sites of
pcDNA5TO (Invitrogen, Inc. Carslbad, CA). To generate vectors expressing full-length
NFI-X1-FLAG and NFI-X3–FLAG, the PCR products were digested with HindIII and
BglII, and cloned into the HindIII/BamHI sites of pCMV5aFLAG (Sigma, St. Louis,
MO). Subsequently, HindIII/XhoI fragments were cloned into the HindIII/XhoI sites of
pcDNA5TO (Invitrogen, Inc. Carlbad, CA). The PCR products containing transactivation
domains of NFI-X1 and NFI-X3 were digested with BamHI and XbaI, and cloned into
the BamHI/XbaI sites of pCGal4.
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2.3.10 Transfections.

Cells were transiently transfected in 12 well clusters using

FuGENE6 transfection reagent (Roche, Indianapolis, IN), according to the supplier’s
instructions. One day after transfection the cells were harvested, protein extracts were
prepared, and the protein concentration was determined by the BCA method (Sigma
Chemical Co., St. Louis, MO).

Chloramphenicol acetyltransferase (CAT) and β-

galactosidase assays were performed as described [134]. Luciferase (Luc) assays were
performed using a Luciferase Reporter Assay Kit (Promega Corporation, Madison, WI).
CAT and Luc activities were normalized to β-galactosidase activity and are means ±
S.E.M. (5-7 determinations). To generate stable clones, 4 µg NFI-X1, NFI-X1-FLAG,
NFI-X3, or NFI-X3-FLAG expression plasmids were transfected into a 10 cm dish of
U373 cells. Clones selected in DMEM containing 75 µg/ml hygromycin were
subsequently pooled. Nucleofection was used to transiently transfect U373 cells. Briefly,
the cells (0.5x106/well of 6-well dish) were trypsinized, collected by centrifugation and
resuspended in 50 µl of T nucleofactor solutionTM (Amaxa, Inc, Gaithersburg, MD). The
respective plasmids (0.8 µg) were added to the solution, and transfection was performed
using a Nucleofector device (Amaxa, Inc, Gaithersburg, MD) with the electrical setting
of T-20. One ml of warm DMEM medium was added, and cells were incubated at 37°C
for 10 min, and transferred to 6-well plates containing culture medium.

Typical

nucleofection efficiencies were greater than 70% with cell viability close to 90%.

2.3.11 Chromatin immunoprecipitation (ChIP) assay. Cells were crosslinked with 1%
formaldehyde for 10 minutes at 37°C and then washed with ice-cold PBS containing 125
mM glycine and 1 mM PMSF. Chromatin was sonicated and immunoprecipitated using

36

specific antibodies exactly as described in the chromatin immunoprecipitation protocol
from Upstate Inc. (Charlottesville, VA). The following antibodies were used: anti-acetylH3 (06-599, Millipore, Billerica, MA), anti-trimethyl-K4H3 (07-473, Upstate), anti-Pol II
(05-623, Millipore), and anti-FLAG (M2) (Sigma, St. Louis, MO). The following primers
were used in the qPCR: 5’-GCATCGCCAGTCTAGCCC-3’ and 5’-ATTCGAGCCAGG
GAGAGGC-3’ for the GFAP promoter and 5’-TGCAAGCAGACCTGGCAGC-3’ and
5’-GCAAGCCCCCTGCTCAATG-3’ for the GFAP enhancer.

2.3.12 M ase protection assay. Three 10 cm dishes of cells were used for nucleosome
mapping. Briefly, cells were trypsinized, washed with cold PBS, and resuspended in 2 ml
60 mM KCl, 15 mM NaCl, 5 mM CaCl2, 10 mM Tris pH 7.4, 300 mM sucrose, 0.1 mM
EDTA, and 0.1% NP-40. Cells were lysed with a dounce homogenizer, nuclei were
pelleted by centrifugation, and subsequently washed with 2 ml MNase digestion buffer
(10 mM Tris pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermidine,
and 1 mM CaCl2). Nuclei were resuspended in 150 µl MNase digestion buffer (with 3
mM CaCl2), 10 u of MNase was added, and samples were incubated for 1 h at 37ºC.
DNA was purified using Puregene DNA purification kit (Qiagen, Valencia, CA). DNA
was analyzed by gel electrophoresis (>95% typically represented mononucleosomal
DNA), and subsequently quantified by qPCR using the Power SYBRGreen PCR kit
(Applied Biosystems, Foster City, CA) and the following primers: (F1) 5’-CAGTGGGG
TGAGGGGAG-3’; (F2) 5’-GCCTCTGGGCACAGTGAC-3’; (F3) 5’-GGCGTGCCCA
GGAAGCTC-3’; (F4) 5’-CACCTGCCTCATGCAGGAG-3’; (F5) 5’-ATGGTCCAACC

37

AACCCTTTC-3’; (R1) 5’-GCGAGGGCTTTATGAAGG-3’; (R2) 5’-TGGGCTAGACT
GGCGATG-3’; and (R5) 5’-GAGGCAGGTGGTACCTGG-3’.
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2.4 RESULTS
2.4.1

FI-X3 splice variant expressed in astrocytes and glioma cells is highly

conserved in mammals.

The structure of the fix gene is highly conserved in

vertebrates, including Xenopus, rodents, canines, and primates. Moreover, the NFI-X
mRNA is alternatively spliced in these species producing several splice variants that have
been either cloned, or are predicted by the in silico analysis (reviewed in [128]). In
vertebrates, one of the splice variants (which we named NFI-X3 due to the homology of
its C-terminal part to the previously cloned Xenopus’s NFI-X3) is generated by the
inclusion of exon 9, which is absent in other splice variants, including NFI-X1 (Fig.
2.2A). The incorporation of exon 9 in the NFI-X3 mRNA generates a frame-shift placing
the alternative exon 11’s STOP codon in frame. As a result, the translated NFI-X3
protein possesses a long proline-rich C-terminal transcription activation (TA) domain,
which is unique to this splice variant (Fig. 2.1 and 2.2A). On the amino acid level, the
TA domain of NFI-X3 is 100% conserved in primates and dogs, while differs by only
three and four amino acids in mice and rat, respectively (Fig. 2.1). In contrast, the NFIX3 TA domain of Xenopus differs by 36 amino acids, including a three amino acid-long
insertion (Fig. 2.1). The functional properties of Xenopus’s NFI-X3 are not substantially
different from the NFI-X1 and NFI-X2 splice variants [116]. However, the absolute
conservation of the TA domain of NFI-X3 in primates (and dog) and over 95% identity in
rodents, suggested that it may have acquired novel functions during the evolution of
mammals. Since the fix gene is important for mouse brain development and regulates
gene expression in human astrocytes, we analyzed whether NFI-X3 is expressed by these
cells. In fact, NFI-X3 was expressed by primary human astrocytes, and at much lower
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levels (5-10%) by glioma cell lines, which represent cells that escaped the astrocyte
differentiation process (Fig. 2.2B and C). Interestingly, glioma cells expressed low levels
of all NFI-X transcripts, with the ratio of NFI-X3 to total NFI-X significantly reduced (by
approximately 60% compared to astrocytes), thus suggesting that NFI-X3 may regulate
gene expression during the differentiation towards astrocytes. In order to analyze the
functions of NFI-X splice variants, we amplified NFI-X3 and NFI-X1 from primary
human astrocytes. The C-terminal TA domains of astrocyte-derived NFI-X1 and NFI-X3
were identical to the software-predicted domains. However, in contrast to Xenopus NFIX3 and human NFI-X1, the N-terminus of human astrocyte-derived NFI-X3 is encoded
by the alternative exon 1a (Fig. 2.2A). Thus, the unique conserved NFI-X3 splice variant
is expressed by astrocytes, and it may be important for the differentiation of these cells.

2.4.2 The TA domain of

FI-X3 is critical for the regulation of gene expression in

human astrocytes and glioma cells. In order to analyze the transactivation potential of
NFI-X3, we used several reporters that respond to NFI proteins [111, 130, 135]. These
reporters were analyzed in transient transfection experiments of primary human
astrocytes, glioblastoma, and HEK293 cells (Fig. 2.3). In addition to NFI-X3, we also
used NFI-X1 to compare the transactivation by these two NFI-X splice variants.
Significantly, NFI-X3, but not NFI-X1 activated the GFAP reporter in both astrocytes
and glioblastoma cells
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Figure 2.1 Alignment of the amino acid sequences of the TA domains of

FI-X3.

Sequences were aligned with the ClustalW program. Dashes represent gaps introduced to
maximize the similarity, grey box indicate identical sequences, while black boxes
indicate sequences that are similar. The full length sequence of human NFI-X3 was
deposited into GenBank (FJ861276). The following sequences were aligned: Macaca
fasicularis

(AB172261),

Macaca

mulatta

(XM_001110545),

Canis

familiaris

(XM_542036), Xenopus laevis [136], Homo sapiens (AAD38241), Mus musculus
(NM_001081981), and Rattus norvegicus (EDL92203).
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Figure 2.2

FI-X3 is expressed by astrocytes and glioma cells. (A) A model of exon

composition of the nfix gene, NFI-X1 and NFI-X3 transcripts (top panel), and the amino
acid sequences of the predicted TA domains (bottom panel). (B, C) RNA was isolated
from primary human astrocytes and the indicated glioma cell lines, reversed transcribed,
and the expression levels of NFI-X3 (left panel) and total NFI-X (right panel) were
analyzed by qPCR as described in the materials and methods. Data were normalized to
GAPDH mRNA, and are presented as a percentage to human astrocytes set as 100%.
NFI-X3 and NFI-X PCR products (after 31 cycles) were also analyzed by agarose gel
electrophoresis (insert shown in B), using the indicated primers (XF and X3R for NFIX3, X1F and X1R for the total NFI-X).
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(Fig. 2.3A); however, this reporter was not functional in HEK293 cells (data not shown).
Since expression levels of both NFI-X3 and NFI-X1 were comparable (Fig. 2.3A, insert),
we conclude that NFI-X3 may be critical for the transcription of GFAP in glial cells. In
fact, the artificial NFI reporter, containing ten NFI binding sites linked to the minimal tk
promoter [130], was similarly activated by 10-fold lower amounts of NFI-X3 than NFIX1 in human astrocytes (Fig. 2.3B). In addition to the activator functions, NFIs also
repress the expression of several genes, including p21(WAF1/CIP1) [135]. Surprisingly,
both NFI-X3 and NFI-X1 efficiently repressed the expression of the p21 reporter in
astrocytes, as well as HEK293 cells (Fig. 2.3C). These data suggest that the activation by
NFI-X3 in glial cells may depend on its unique TA domain; however, the repression is
likely mediated by a different part of the molecule, since the TA domains of NFI-X1 and
NFI-X3 are very different (Fig. 2.2A). To test these TA domains, we fused them to the
Gal4 DNA binding domain (Fig. 2.4A), and co-transfected these constructs into
astrocytes and HEK293 cells with the reporter plasmid p5xGAL4-luc, which contains
five Gal4 binding sites linked to the Firefly luciferase gene [133]. The fusion protein
containing the TA domain of NFI-X1 could not induce the Gal4 reporter either in
astrocytes or HEK293 cells (Fig. 4B). In contrast, the fusion protein containing the TA
domain of NFI-X3 activated the Gal4 reporter in both cell types (2.5 and 125 fold) (Fig.
2.4B). Thus, the TA domain of NFI-X3 substantially differs in function from the one
present in NFI-X1, and may regulate the expression of target genes in astrocytes.
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Figure 2.3 Differential effects of

FI-X3 and

FI-X1 on various gene reporters.

Primary human astrocytes and HEK293 cells were transiently transfected, while U373
were nucleofected as described in the materials and methods. Cells were transfected or
nucleofected with 100 ng of the indicated reporter plasmids, 400 ng NFI-X1 or NFI-X3
expression vectors (A), or the indicated amounts of the expression vectors (B, C), as well
as 50 ng β-galactosidase expression vector.

One day after transfection, cells were

harvested. CAT or LUC activities were normalized to β-galactosidase activities to
account for transfection efficiency. The putative binding sites for NFI, AP-1, p53, and
SP1 are depicted on the cartoons representing the reporters. tk indicates a thymidine
kinase minimal promoter. Inserts show the expression levels of NFI-X1 and NFI-X3.
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Figure 2.4 Comparison of the activities of TA domains of

FI-X1 and

FI-X3.

Primary human astrocytes were transiently transfected with 100 ng p5xGAL4-Luc, 400
ng of the indicated expression plasmids, and 50 ng β-galactosidase expression vector.
One day after transfection, cells were harvested. LUC activities were normalized to βgalactosidase activities to account for transfection efficiency. Insert shows the expression
levels of fusion proteins. Experiments were performed three times in duplicates.
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2.4.3 Regulation of

FI-X3 expression during astrocyte differentiation. We have

recently developed an in vitro astrocyte differentiation model that allows the analysis of
mechanisms regulating astrocyte-specific gene expression [121]. We used BG01V
embryonic stem cells (ESC), differentiated them into neural progenitors (NP), and
thereafter to astrocytes (Fig. 2.5). ESC and NP expressed only minute amounts of NFI-X
(all NFI-X transcripts), including NFI-X3 (Fig. 2.5, top right panel). However,
differentiation of NP to astrocytes resulted in the significant activation of NFI-X
expression (~20 fold after 21 days), with even greater expression of the NFI-X3 (~37 fold
in 21 days). The expression of NFI-X3 preceded the expression of two markers of late
astrocyte differentiation, GFAP and SPARCL1 (Fig. 2.5, bottom panels), therefore
suggesting that NFI-X3 may regulate gene expression during the final stages of astrocyte
differentiation.

2.4.4 FI-X3 specifically regulates the expression of GFAP and SPARCL1 in human
astrocytes and glioma cells. In order to evaluate whether NFI-X3 regulates the
expression of GFAP and SPARCL1, we designed siRNA specifically targeting exon 9 of
the nfix gene (Fig. 2.6A). For comparison, NFI-X SMARTPool siRNA was used to
knock-down the expression of all NFI-X splice variants. In primary human astrocytes, the
siRNA targeting exon 9 of the nfix gene efficiently and specifically knocked-down the
expression of NFI-X3 (by 95%); however, this siRNA only diminished the expression of
total NFI-X by 10% (Fig. 2.6A), and had no effect on the expression of NFI-A, -B, and C (data not shown). These results indicate that mRNA encoding NFI-X3 constitutes at the
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Figure 2.5

FI-X3, GFAP, and SPARCL1 are coexpressed during the

differentiation of astrocytes. Embryonic stem cells (ESC) were differentiated into
neural progenitors (NP), and then into astrocytes for 24 days as described in the materials
and methods. RNA was isolated during this process every 3 days, reverse-transcribed,
and the expression of NFI-X3, NFI-X, GFAP, and SPARCL1 was analyzed by qPCR.
Target gene expression was normalized to GAPDH levels, and is represented as a fold
induction in reference to NP cells. Experiments were performed three times in triplicates.
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Figure 2.6

FI-X3 regulates the expression of GFAP and SPARCL1 in primary

human astrocytes. Human astrocytes were transfected with 10 nM non-targeting siRNA
(si-con), 10 nM siRNA targeting NFI-X3 (si-NFI-X3), or 10 nM siRNA targeting all
NFI-X transcripts (si-panNFI-X). RNA was isolated after 48 hours and the expression of
NFI-X3 and total NFI-X (A) and GFAP and SPARCL1 (B) were analyzed in triplicates.
Data were normalized to GAPDH mRNA, and are presented as a fold induction in
reference to untreated differentiated astrocytes.
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most approximately 10% of the total pool of the NFI-X mRNAs in astrocytes. More
importantly, the NFI-X3 knock-down resulted in the inhibition of GFAP and SPARCL1
expression by 40% and 50%, respectively, which is almost identical to the repression
found using siRNA targeting total pool of the NFI-X (Fig. 2.6B).
Next we analyzed whether stable overexpression of NFI-X3 and NFI-X1 can induce
the expression of GFAP and SPARCL1 in glioma cells. We have chosen U373 cells,
which express relatively low levels of both of these markers, and generated pools of cells
overexpressing NFI-X3 and NFI-X1 (Fig. 2.7A). Both of these cell pools upregulated the
expression of GFAP and SPARCL1; however, overexpression of NFI-X3 resulted in
massive induction of both markers, while overexpression of NFI-X1 had only a moderate
effect (Fig. 2.7A and B). The data of the knock-down and overexpression experiments
suggest that NFI-X3, although accounting at the most for only 10% of total NFI-X but
possessing much greater transactivation potential than NFI-X1, regulates the expression
of GFAP and SPARCL1 in both human astrocytes and glioma cells.

2.4.5 Alterations in the architecture of the +1 nucleosome at the GFAP promoter are
induced by the unique TA domain of

FI-X3. Recently, NFI-A has been shown to

induce dissociation of DNA methyltransferase 1 from the gfap regulatory region and
demethylation of the STAT3 binding site that is critical for the induction of GFAP
expression [25]. To examine whether NFI-X3 activates GFAP expression via a similar
mechanism, we analyzed methylation of CpGs at the gfap gene in the pools of cells
expressing either vector, NFI-X3 or NFI-X1 (Fig. 2.8A). However, all of the analyzed
CpG, including the one located within the STAT3 binding element, were unmethylated in
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Figure 2.7 Overexpression of

FI-X3 but not

FI-X3∆
∆ dramatically induces the

expression of GFAP and SPARCL1 in glioma cells. Pools of U373 stable clones
transfected with plasmids expressing either NFI-X1, NFI-X3, NFI-X3∆, or empty vector
were cultured as described in materials and methods. RNA and cell lysates were prepared
from the duplicate cultures, and media were collected. (A) The expression of NFIs,
GFAP (cell lysates), and SPARCL1 (medium) was analyzed by western blotting. (B)
RNA was reverse transcribed, and the expression of GFAP and SPARCL1 was analyzed
by qPCR.
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Figure 2.8

FI-X3 induces the recruitment of R A PolII to the gfap promoter. (A)

DNA was isolated from U373-Vec, U373-NFI-X1 and U373-NFI-X3 cells, bisulfite
converted, and methylation of suitable CpG was analyzed as described in the materials
and methods. Empty circles indicate demethylated CpGs. (B) Lysates from U373-Vec,
U373-NFI-X1-FLAG and U373-NFI-X3-FLAG cells were immunoprecipitated with antiFLAG antibodies, and precipitates were analyzed by western blotting using anti-CBP and
anti-NFI antibodies (insert). ChIP was performed using chromatin prepared from U373Vec, U373-NFI-X1 and U373-NFI-X3 cells, or U373-Vec, U373-NFI-X1-FLAG and
U373-NFI-X3-FLAG cells as indicated. Both the gfap enhancer and core promoter were
analyzed for the presence of acetylated-histone H3, trimethylated-K4H3, RNA PolII, and
NFI-X1 or NFI-X3 (anti-FLAG) using the antibodies described in the materials and
methods. NRS indicates normal rabbit serum used for immunoprecipitation. Results are
shown as a percentage of input. Experiments were performed three times.
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of histone acetyltransferases by the STAT3/SMAD1 complex followed by acetylation of
histones at the promoters of astrocyte-specific genes is another mechanism of their
activation [114]. However, despite drastically different activation of the gfap gene by
NFI-X3 and NFI-X1 (Fig. 2.7), both of this splice isoforms similarly interacted with CBP
(Fig. 2.8B insert). Furthermore, histone acetylation at the gfap enhancer as well as core
promoter was comparable in vector, NFI-X3, and NFI-X1 clone pools as determined by
ChIP analysis (Fig. 2.8B) excluding histone acetylation as a mechanism of activation.
Nevertheless, the recruitment of RNA PolII to the gfap promoter was significantly
increased in NFI-X3 expressing cells, which also correlated with the increased histone
H3 Lys4 trimethylation indicating ongoing transcription (Fig. 2.8B).

The increased

recruitment of RNA PolII could be a result of stronger binding of NFI-X3 than NFI-X1 to
the NFI binding elements. To examine the binding of both of these splice variants at the
gfap regulatory regions, we generated U373 pools expressing FLAG-tagged NFI-X1 and
NFI-X3. As expected, GFAP and SPARCL1 expression was strongly activated in NFIX3-FLAG expressing cells (Supplementary data Fig. 2.1). Nevertheless, binding of both
NFI-X1-FLAG and NFI-X3-FLAG to the gfap enhancer was similar (Fig. 2.8B), while
they did not bind to the gfap promoter as previously reported [130].
Nucleosomes are an impediment to transcription and therefore they are evicted or
remodeled during gene activation [137, 138]. To understand the mechanism of NFI-X3induced activation of GFAP expression, we analyzed nucleosome positioning and
occupancy at the gfap promoter using MNase protection assay combined with qPCR
[139]. The +1 nucleosome was positioned at approximately -130 to +20 relative to the
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gfap transcription start site in vector, NFI-X3, NFI-X3∆, and NFI-X1 clone pools (Fig.
2.9A, and data not shown).

The upstream -1 nucleosome was also positioned at

approximately -300 to -150 in the three cell types, indicating that both -1 and +1
nucleosomes are not repositioned in cells overexpressing vector, NFI-X1, NFI-X3 or
NFI-X3∆.

Subsequently, we analyzed the relative occupancy of the -1 and +1

nucleosomes in all four cell types.

Although the accessibility of DNA to MNase

cleavage at the -1 and +1 nucleosome was increased in NFI-X1 and NFI-X3
overexpressing cells, the accessibility was significantly greater in NFI-X3 overexpressing
cells (Fig. 2.9B). More importantly, the accessibility of DNA to MNase cleavage of
vector and NFI-X3∆ overexpressing cells was similar (Fig. 2.9B). Since NFI-X1 and
NFI-X3 differ by their TA domains, we conclude that the unique TA domain of NFI-X3
induces stronger local changes in the promoter nucleosome architecture that allow for the
increased RNA PolII recruitment and subsequent activation of GFAP expression.
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Figure 2.9

FI-X3 induces alterations in the nucleosome architecture at the gfap

promoter. Nuclei were isolated from U373-Vec, U373-NFI-X1, U373-NFI-X3, and
U373-NFI-X3∆ cells and digested with MNase as described in the materials and
methods. (A) The positions of mapped -1 and +1 nucleosomes are indicated, and
locations of qPCR primers are shown. qPCR reactions were performed on MNasetreated and total genomic DNA of U373-Vec cells, and the differences in Ct values are
shown relative to the F5R5 qPCR product (Ct values for F5R5 were identical for genomic
and MNase-treated DNA). (B) qPCR reactions were performed on both MNase-treated
DNA of U373-Vec (vec), U373-NFI-X1 (X1) , U373-NFI-X3 (X3), and U373-NFI-X3∆
(∆) cells as indicated, and the differences in Ct values are shown relative to the -3kb
qPCR product. (C) Model of transcriptional activation of the gfap gene expression by
NFI-X3. DNA is demethylated at the gfap enhancer, which allows for binding of the AP1, NFI-X1/NFI-X3, and STAT3 in U373-NFI-X1/NFI-X3 cells. At the gfap promoter
histones are similarly acetylated in U373-NFI-X1 and U373-NFI-X3 cells. However, the
unique TA domain of NFI-X3 induces stronger alteration of the nucleosome architecture
(either remodeling or eviction) that allows for both the increased PolII occupancy and
transcription of the gfap gene.
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Supplemental Figure 2.1 Overexpression of FI-X3-FLAG dramatically induces the
expression of GFAP and SPARCL1 in glioma cells. Pools of U373 stable clones
transfected with plasmids expressing either NFI-X1-FLAG, NFI-X3-FLAG, or empty
vector were cultured as described in materials and methods. RNA was prepared from the
duplicate cultures and was reverse transcribed, and the expression of GFAP and
SPARCL1 was analyzed by qPCR.

64

65

2.5 DISCUSSIO
It is apparent that NFIs are critical for the proper development of the brain,
nevertheless the vital target genes regulated by NFIs and the molecular mechanisms of
their regulation remain elusive. To date, multiple NFI-responsive genes have been
identified in the brain, including the genes encoding GFAP, ACT, SPARCL1, S100B in
astrocytes [28, 29, 121, 130], brain fatty acid binding protein in radial glial cells [35],
myelin basic protein in oligodendrocytes [140], and mid-sized neurofilament in neurons
[141]. Since regulatory sequences of these genes can bind all NFIs, their transcriptional
regulation in a given cell type, in part, may depend on the availability of a particular NFI
isoform, presence of the specific splice-variant, and likely the acquired posttranscriptional modifications of the NFIs. In fact, NFIs are expressed in complicated
patterns during embryogenesis [27, 142], with NFI-A and NFI-B expressed during early
gliogenesis [18], while NFI-X and NFI-C expressed later in the differentiation of
astrocytes and control the expression of late astrocyte markers [121]. NFIs are also
phosphorylated, and this modification affects their function [35].
To date, the functional importance of the multiple NFI splice variants, as well as the
mechanisms controlling their generation, remain largely unknown. Significantly, the NFI
splice variants are evolutionary conserved in mammals, and their splicing mostly affects
the C-termini encoding their TA domains: thus, suggesting that these variants likely
fulfill very specific biological functions [128]. In particular, the inclusion of the exon 9
found in the NFI-A, NFI-B, and NFI-C generates a subset of relatively active
transcription factors (NFI-A1, NFI-B1, CTF-1). In contrast to these isoforms, the
importance of alternative splicing of the NFI-X transcript was controversial, since
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Xenopus and mouse splice variants containing exon 9 were reported not to be particularly
active [116, 136]. However, the TA domain of Xenopus NFI-X3 is drastically different
than the TA of the X3 variants found in mammals (Fig. 1). Moreover, the repressive
properties of the previously cloned mouse NFI-X3 can be attributed to the partial TA
domain that lacks 14 C-terminal amino acids [136]. In fact, the full length TA domain of
the X3 splice variant is remarkably conserved in mammals, with 100% identity in
primates and dog, and contains seventeen conserved proline residues (Fig. 2.1). These
proline residues are likely responsible for the relatively strong activation of both the
GFAP and NFI reporters by NFI-X3 in astrocytes and glioma cells (Fig. 2.3A and B),
activation of GFAP and SPARCL1 expression in differentiating astrocytes (Fig. 5), and
activation of GFAP and SPARCL1 expression in cells overexpressing NFI-X3 (Fig. 2.7).
This is further supported by the findings that the Gal4 fusion protein containing the NFIX3 TA domain efficiently activated Gal4 reporter (Fig. 2.4), while siRNA specific to
exon 9 (present in NFI-X3) abolished the activation of GFAP and SPARCL1 expression
(Fig. 2.6). In contrast, NFI-X1 did not activate the GFAP reporter in astrocytes and
glioma cells (Fig. 3A), mildly activated the NFI reporter in astrocytes (with
approximately ten times lower efficiency than NFI-X3) (Fig. 3B), and only marginally
activated SPARCL1 and GFAP expression when stably overexpressed in glioma cells
(Fig. 2.7). Moreover, a fusion protein containing the NFI-X1 TA domain, and the Gal4
DNA binding domain did not activate the Gal4 reporter (Fig. 2.4). These data suggest
that NFI-X3 serves as strong transcriptional activator, while NFI-X1 is either a repressor
or a very weak activator. Surprisingly, both NFI-X1 and NFI-X3 repress some genes
independently of their TA domains, as observed for the p21 reporter (Fig. 2.3C) and p21
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mRNA in cells overexpressing NFI-X1 and NFI-X3 (data not shown), nevertheless the
mechanism of repression remains to be established.
The question remains as to whether NFI-X3 plays an important biological role. Our
data argue that NFI-X3 is solely responsible for the NFI-X-mediated regulation of GFAP
and SPARCL1 expression in primary human astrocytes, since the down-regulation of
NFI-X3 expression has an identical effect as the down-regulation of expression of the
total NFI-X pool (Fig. 2.6). Although, NFI-X3 mRNA accounts at the most for only
approximately 10% of the NFI-X mRNAs (Fig. 2.6A), the 10 times stronger activation
potential (Fig. 2.3B) may explain its critical role in gene regulation. Moreover, the
expression of NFI-X3 is strongly upregulated during the differentiation of NP towards
astrocytes, and precedes the activation of GFAP and SPARCL1 expression (Fig. 2.5).
Importantly, the ratio of NFI-X3 mRNA/total NFI-X mRNA increases approximately two
fold during the differentiation (Fig. 2.5). Conversely, this ratio is decreased in various
glioma cells, already expressing low levels of all NFI-X transcripts (Fig. 2.2C), which
may be viewed as cells that exited astrocyte differentiation. However, NFI-X3 expression
is not restricted to glia, since we were also able to detect NFI-X3 mRNA in other nonglial cells (data not shown); thus, indicating that NFI-X3 likely regulates transcription in
various cell types.
Although NFIs were discovered over two decades ago [143], the molecular
mechanism of NFI-mediated gene activation still remains elusive. Interestingly, NFIs not
only bind to their specific binding elements within the regulatory regions of target genes
but also interact with other transcription factors [144] and histone H3 [145]. Importantly,
NFI-C (CTF-1) binding to histone H3, in part, depends on its TA domain [145]. NFI-C
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can also be immunoprecipitated with remodeling complexes containing Brg1 [146],
suggesting that chromatin remodeling may be the mechanism regulating NFI-dependent
transcription. Recently, the induction of the c-fos gene by MAP kinase signaling has
been shown to depend on the acetylation relay switch that induces a local change in the
nucleosome architecture allowing for NFI binding [147]. Nevertheless, how NFI
recruitment increases c-fos expression is not clear. Our data allow us to postulate a novel
NFI-X3-specific model of gene activation that uniquely depends on the TA domain of
NFI-X3.

Our data suggest that NFI-X3, but not NFI-X1, induces changes in the

structure/occupancy of the +1 nucleosome positioned at the transcription start site of the
gfap gene (Fig. 2.9B).

This localized alternation is likely an eviction of the +1

nucleosome from the gfap promoter, which subsequently allows for the increased binding
of the general transcription factors and the recruitment of PolII. However, due to the
limitations of MNase accessibility assay, the NFI-X3-dependent remodeling of the +1
nucleosome cannot be excluded.
In summary, our data suggest that NFI-X3 is a critical splice variant of the nfix gene,
which regulates expression of late markers such as GFAP in astrocytes via a splice
variant-specific mechanism that depends on the induction of local alteration in chromatin
architecture.
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CHAPTER 3
REGULATIO A D ROLE OF YKL-40 I GLIAL CELLS

3.1 ABSTRACT
Expression of a secreted glycoprotein YKL-40 is upregulated in various cancers,
including highly invasive glioblastoma multiforme (GBM); however, functions of YKL40 and its regulation in the nervous system remained unexplored. Here, we report that
YKL-40 expression is activated during mouse brain developmental and also during the
differentiation of neural progenitors into astrocytes in vitro. In primary astrocytes, YKL40 expression is controlled by nuclear factor I-X (NFI-X) and signal transducer and
activator of transcription 3 (STAT3), which are known to regulate gliogenesis. Indeed,
knock-down of NFI-X and STAT3 significantly reduced YKL-40 expression in
astrocytes, while overexpression of NFI-X3 (a splice isoform of NFI-X) dramatically
induced YKL-40 expression in glioma cells. In addition, activation of STAT3 by
oncostatin M induced YKL-40 expression in astrocytes, while overexpression of
dominant-negative STAT3 had a suppressive effect. Interestingly, STAT3 activated
YKL-40 expression via its binding site located in the YKL-40 proximal promoter,
whereas direct NFI-X binding had not been detected. Surprisingly, NFI-X and STAT3
physically interact and this complex likely regulates YKL-40 expression in astrocytes.
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We further show that NFI-X controls migration and invasion of astrocytes and glioma
cells, respectively, by regulating YKL-40 expression. These novel data suggest that
YKL-40 is expressed by astrocytes during brain development and controls astrocyte
migration.
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3.2 I TRODUCTIO
YKL-40, also known as chitinase 3-like-1 (Chi3L1), human cartilage glycoprotein
39 (HcGP-39), and breast regression protein-39 (BRP-39), is a secreted glycoprotein
expressed in both vertebrates and invertebrates [148, 149]. It belongs to the 18glycosylhydrolase family of proteins, but lacks glycolytic properties. It is secreted by a
variety of cell types including macrophages, neutrophils, monocytes, chondrocytes,
synovial cells, smooth muscle cells, endothelial cells, and several solid tumor cells
including GBMs, osteosarcoma, and ovarian carcinoma [90, 91]. The biological functions
of YKL-40 in normal physiological conditions remain poorly explored except that
purified YKL-40 stimulates cell proliferation of several cell types including chondrocyte
s, and synovial cells [91]. It is also known to be an adhesion and migratory factor for
vascular smooth muscle cells, and endothelial cells [91]. Recently, an elegant study
demonstrated that YKL-40 can work as an angiogenic factor [98].
Its expression is elevated in patients with a wide array of pathologies
characterized by tissue destruction, ongoing inflammation, and development of fibrosis
implicating its role in inflammatory processes and tissue remodeling. These pathologies
include atherosclerosis, rheumatoid arthritis, osteoarthritis, giant cell arthritis, and
sarcoidosis [91]. In agreement with its role in inflammation, YKL-40 knock out mice
(BRP-/-) significantly lack antigen-induced Th2 responses [94]. Its expression is activated
during the differentiation of macrophages and smooth muscle cell [92]. Several putative
transcription factor binding sites including Sp-1, Stat, AP-1, CEBP, NF-kB and ETS have
been predicted within the YKL-40 promoter region [92]. Among these, Sp-1 is
responsible for YKL-40 expression during macrophage differentiation [92]. Several
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cytokines including IL-1, TNF-α, and IL-6 can modulate its expression in many cell
types including chondrocytes, macrophages, and GBMs [95] [93]. Increased levels of
YKL-40 have been observed in a variety of central nervous system (CNS) pathologies
including Alzheimer’s disease (AD), and HIV associated dementia [103]. However, little
is known about the source, regulation and role of YKL-40 in the CNS.
Astrocytes constitute the majority of CNS cells and play critical roles in normal
and pathology associated brain functions. Nevertheless, factors expressed, their
regulation, and role during the astrocyte differentiation are only partially known. The
astrocyte differentiation process is controlled by several signaling pathways, including
the JAK-STAT pathway, BMP-SMAD pathway, and the Notch-HES pathway. Direct
activation of JAK-STAT3 by IL-6 family cytokines, including, CT-1, LIF and OSM
enhances astrocyte differentiation from neural precursor cells in vitro [17, 150]. In
addition, a family of transcription factors called NFI (nuclear factor one) has also been
shown to control astrocyte differentiation [18, 151]. NFI family consists of four members
namely NFI-A, -B, -C, and –X. In mice, NFI family members are expressed in an
overlapping pattern during embryogenesis, with high levels of NFI-A, -B, and -X
expression in the developing neocortex [119]. In agreement to their expression, fia, fib
and fix knock out mice show severe brain anatomical defects, including agenesis of
corpus callosum [119, 142]. In addition, postnatal analysis of the fix null animals show
defects in progenitor cell proliferation or migration [119]. Recently, NFI-A and –B has
been shown to control gliogenesis in chick embryonic spinal cord, and we have recently
shown that NFI-C and –X regulate the expression of late astrocyte marker genes during
the astrocyte differentiation of human neural progenitors invitro [18, 151]. Furthermore,
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to add to the complexity, NFI family members undergo alternative splicing to generate as
much as 9 different variants from each gene. We have recently cloned and characterized a
novel human splice isoform of NFI-X called NFI-X3, which is a potent activator due to
its unique proline rich transactivation domain, regulating astrocyte marker gene
expression (Singh SK Submitted). Although, JAK-STAT3 pathway and NFIs are critical
regulators of astrocyte differentiation, the expression and function of their downstream
target genes during astrocyte differentiation remain elusive.
In this study, we show that YKL-40 is expressed and activated during the early
period of postnatal mouse brain development, and also during astrocyte differentiation in
vitro. Furthermore, its expression is regulated by NFI-X, and STAT3, the well known
regulators of astrocyte differentiation. Functionally, YKL-40 works as a migration and
invasion factor for astrocytes and glioma cells, respectively. We propose that YKL-40 is
expressed during astrocyte differentiation and controls astrocyte migration to the proper
location in the developing brain. This normal function of YKL-40 is utilized by glioma
cells to migrate and invade surrounding tissue.
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3.3 MATERIALS A D METHODS
3.3.1 Cell culture. Human BG01V embryonic stem cells (ATCC, Rockville, MD) were
cultured on mitomycin C-inactivated mouse embryonic fibroblast (MEF) layer. Cells
were cultured in DMEM/F12 medium, supplemented with 20% knockout serum
replacement (Gibco, Grand Island, NY), 1 mM L-glutamine, 0.1 mM nonessential amino
acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 4 ng/ml basic fibroblast growth factor
(bFGF) (PeproTech, Rocky Hill, NJ), and 0.1 mM β-mercaptoethanol. Cells were
propagated in 4 day cycles, and enzymatically passaged with collagenase and trypsin.
Human cortical astrocyte cultures were established using dissociated human cerebral
tissue as previously described [129]. Cortical tissue was provided by Advanced
Bioscience Resources (Alameda, CA), and the protocol for obtaining postmortem fetal
neural tissue complied with the federal guidelines for fetal research and with the
Uniformed Anatomical Gift Act. Human glioblastoma U373-MG cells were obtained
from American Type Culture Collection (Rockville, MD) while human glioma LN229
cells were obtained from Dr. Dimitry Kopitiniv (VCU, Richmond, VA). Cells were
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf
serum, antibiotics, sodium pyruvate, and non-essential amino acids.
3.3.2 Generation of neural progenitors. BG01V neural progenitors were generated
exactly as described previously [121]. Briefly, cells were grown in DMEM/F12,
supplemented with 15% defined FBS (Hyclone, Logan, UT), 5% KSR, 2 mM Lglutamine, 0.1 mM nonessential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin,
4 ng/ml bFGF, and 10 ng/ml leukemia inhibitory factor (LIF) (Chemicon, Temecula,
CA). Subsequently, cells were grown for 7 days in differentiation medium composed of
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DMEM/F12, N2 supplement (Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml
penicillin, 50 µg/ml streptomycin, and 4 ng/ml bFGF. Subsequently, the MEF layer was
removed and cells were dissociated by DPBS without calcium and magnesium, followed
by collagenase and trypsin incubation. Cells were then plated on laminin and poly-Lornithin coated dishes, propagated in NB27 medium consisting of neurobasal medium,
B27 supplement (both from Gibco, Grand Island, NY), 2 mM L-glutamine, 50 U/ml
penicilin, 50 µg/ml streptomycin, 20 ng/ml bFGF, and 10 ng/ml LIF. Cells were
maintained by passaging using trypsin.
3.3.3 Differentiation into astrocytes. To generate astrocytes, neural progenitors were
cultured on laminin and poly-L-ornithine coated dishes in DMEM, supplemented with
10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, and
nonessential amino acids for 21-24 days.
3.3.4 Cytokines and Cell Stimulation. Cells were stimulated with 25 ng/ml OSM, or 25
ng/ml IL-6 And sIL-6R (R&D, Systems, Inc., Minneapolis, MN.
3.3.5 Down-regulation of target genes. Expression of NFI, NFI-X, STAT3, STAT1,
YKL-40, c-Fos, Fra-1 and c-Jun mRNAs was down-regulated using SmartPool siRNAs
(si-pan-NFI, si-panNFI-X, si-Stat3, si-Stat1, si-YKL-40, si-cFos, si-Fra-1 and si-cJun)
from Dharmacon (Dharmacon, Int., Lafayette, CO). The NFI-X3-specific siRNAs (siNFI-X3) was designed (Software provided on Dharmacon’s Website) to specifically
target mRNA encoded by exon 9 (5’-UCCUAUG CCUGAUUCCAAAUU-3’). siRNA
was transfected into astrocytes, and U373-X3 cells using Dharmafect 1, according to the
manufacturer’s instructions.
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3.3.6 R A isolation and quantitative PCR. Total cellular RNA was prepared by Trizol
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Subsequently, 1 µg of
total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA). YKL-40, NFI-X, c-Fos and GAPDH mRNA levels were
measured using pre-mixed primer-probe sets, and TaqMan Universal PCR Master Mix
according to the supplier’s instructions (Applied Biosystems, Foster City, CA). The
cDNAs were diluted 10-fold (for the target genes) or 100-fold (for GAPDH), and
amplified using the ABI 7900HT cycler. Gene expression levels were normalized to
GAPDH mRNA levels, and presented as a fold induction with mean values +/- standard
deviation. Statistical analysis was performed by one-way analysis of variance.
Differences were considered statistically significant when p-values were <0.05.
3.3.7 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2
mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany). Samples were
resolved using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher
& Schuell, Keene, NH). The anti-YKL-40, anti-NFI and anti-β-tubulin antibodies were
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and anti-Stat3 antibody from Cell
Signaling Technology. Antigen-antibody complexes were visualized by enhanced
chemiluminescence using Immobilon Western blotting kit (Millipore, Temecula, CA).
3.3.8 Co-Immunoprecipitation. Protein lysates were prepared as described above.
Briefly, lysates containing 200-300 µg protein were precleared with 25 µl of the protein
G Sepharose 4 fast flow beads (GE Healthcare, Uppsala) for 1 hour. The precleared
lysates were then incubated with 2 µg of anti-NFI antibody overnight at 40C.
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Subsequently, 30 µl of protein G sepharose beads were added and incubated for 1 h at
40C. Beads were extensively washed with the lysis buffer and immunoprecipitated
protein was eluted in sample buffer at 950C for 5 min.
3.3.9 Synthetic oligonucleotides. The following oligonucleotides were synthesized to
mutate the STAT binding site in the YKL-40-Luc reporter (pStat-mutYKL-40 Luc) 5’ACATGCTAGCAAGCCCCCATCATCACCC-3’

and

5’-

GCTTGCTAGCATGTGACTCAGCCGCATTTCC-3’. The mutation in NFI binding site
was

generated

by

the

following

synthesized

oligonucleotides

TCCACGAGCTCAAGGGGCCTGGAGTGAATGC-3’

and

5’5’-

CCCTGAGCTCGTGGAAACTGGGCTCAATTTAG-3. The following oligonucleotides
were

synthesized

for

the

labeling,

followed

by

EMSA

experiments

GATCTCCACCTGGCCAGGGGCCTGGAGTGA-3’

and

GATCTCACTCCAGGCCCCTGGCCAGGTGGA-3’

(-467_NFI);

5’5’-

and

5’-

GATCTTCAAGTTCCCATAAAAGGA-3’ (-155_STAT3).
3.3.10

uclear extract preparation and EMSA. Nuclear extract from astrocytes and

U373-X3-FLAG cells were prepared as described [151]. Double-stranded DNA
fragments were labeled by filling in the 5′-protruding ends with Klenow enzyme using
[α-32P]dCTP (3000 Ci/mmol). EMSA was carried out according to the published
procedures [151]. Briefly, 5 µg of nuclear extracts and ∼10 fmol (10,000 cpm) of probe
were used. The competition experiment was performed in the presence of a 100-fold
excess of the cold oligonucleotides. anti-NFI (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-STAT3 (Cell Signaling Technology, Danvers, MA), and anti-Flag(M2)
(Sigma-Aldrich, Saint Louise, MO) antisera were used for the supershift studies.
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3.3.11 Plasmids. The pYKL(-1300)Luc reporter was provided by Dr. Michael Rehli
(University of Regensberg, Germany) (7). The STAT mutant plasmid pSTATmut1YKL40 Luc, pSTATmut2YKL-40 Luc and NFI mutant plasmid pNFImutYKL-40 Luc were
generated using a Quick Change II site-directed mutagenesis kit (Stratagene, Cedar
Creek, TX) and using the oligonucleotides described in the synthetic nucleotides section.
The generation of plasmids expressing NFI-X1, and NFI-X3 are described elsewhere
(Singh SK et. al submitted).
3.3.12 Transfections.

Cells were transiently transfected in 12 well clusters using

FuGENE6 transfection reagent (Roche, Indianapolis, IN), according to the supplier’s
instructions. One day after transfection the cells were harvested, protein extracts were
prepared, and the protein concentration was determined by the BCA method (Sigma
Chemical Co., St. Louis, MO). Luciferase (Luc) assays were performed using a Dual
Luciferase Reporter Assay Kit (Promega Corporation, Madison, WI). Luc activities were
normalized to Renilla Luciferase activity (Promega Corporation, Madison, WI) and are
means ± S.E.M. (5-7 determinations). Generation of stable cells overexpressing NFI-X1,
NFI-X3 and NFI-X3-FLAG are described elsewhere (Singh SK et. al. submitted).
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3.4 RESULTS
3.4.1 Expression of YKL-40 is activated during both mouse brain development and
astrocyte differentiation in vitro. YKL-40 is expressed during the development of
various tissues including cartilage [91]. Since YKL-40 is expressed in glioblastomas, we
analyzed its expression during mouse brain development. Indeed, YKL-40 expression
gradually increases during the postnatal brain development at both RNA and protein
levels (Fig. 3.1A, B), with YKL-40 mRNA levels increased approximately 7 fold at
postnatal day 21 (P21) compared with P1.
Since, astrocytes comprise the majority of the cells present within the brain and
are generated during the late embryonic and early postnatal brain development [152], we
explored whether these cells account for the YKL-40 expression. We have analyzed the
expression of YKL-40 during the differentiation of human ESC towards NP and
astrocytes in vitro [151]. Interestingly, YKL-40 is expressed at very low levels in ESCs
and in NPs (Fig. 3.1C). However, the expression of YKL-40 is dramatically induced
(approximately 60 fold) during the differentiation of NPs towards astrocytes (Fig. 3.1C).
These data demonstrate that YKL-40 is expressed during astrocyte differentiation and
also during mouse brain development.

3.4.2

FI-X3 regulates the expression of YKL-40 in astrocytes and glioma cells. We

have previously shown that NFI-C and NFI-X regulates the expression of terminal
astrocyte markers, including GFAP and SPARCL1 in primary human astrocytes and
human NP differentiating towards astrocytes [151]. We sought to explore whether NFIs
also regulates YKL-40 expression. We specifically knocked-down the expression of
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individual NFI members as well as the transcripts of all the NFI members together in
astrocytes. In accordance, down regulation of NFI-X significantly reduced YKL-40
expression (Fig. 3.2A). Furthermore, we have previously reported NFI-X3 a splice
isoform of NFI-X predominantly controls astrocyte marker gene expression (Fig. 2.6,
2.7). Indeed, we down-regulated NFI-X3 as well as the total pool of NFI-X in primary
human astrocytes. Significantly, down-regulation of NFI-X as well as NFI-X3 resulted in
the 50% and 30% reduction of YKL-40 expression, respectively (Fig. 3.2B).
Next we analyzed the expression of YKL-40 in glioma cells (LN229) stably
overexpressing either NFI-X1 or NFI-X3 splice isoform. NFI-X1 had a marginal effect
on YKL-40 expression; however, NFI-X3 dramatically induced YKL-40 levels by 1500
fold (Fig. 3.2C). To exclude the possibility of cell line specific effects, we stably
overexpressed either NFI-X1 or NFI-X3 in U373 glioma cells and analyzed the
expression of YKL-40. Similarly, NFI-X3, but not NFI-X1, strongly induced YKL-40
expression (Fig. 3.2D and E) excluding the possibility of a cell line specific effect. These
results strongly suggest that NFI-X3 regulates YKL-40 expression in astrocytes and
glioma cells.
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Figure 3.1 YKL-40 is expressed during early postnatal mouse brain development
and human astrocyte differentiation invitro. YKL-40 expression in total brain
homogenate was analyzed by western blotting (A) and qPCR (B) at the indicated times of
mouse brain development. (C) Human embryonic stem cells (ESC) were differentiated
into neural progenitors (NP) and subsequently to astrocytes. RNA was isolated every 3
days (d), and the expression of YKL-40 was analyzed by qPCR. Target gene expression
was normalized to GAPDH mRNA, and is represented as a fold induction in reference to
NPs.
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Figure 3.2

FI-X3 regulates YKL-40 expression in glioma cells and primary

astrocytes. RNA was isolated from astrocytes transfected with indicated si-RNA for 48
hours and the expression of YKL-40 was measured by q-PCR. Data is presented as the
fold change of control si-RNA (Si-Con) cells (A). (B) Primary astrocytes were
transfected with either scrambled si-RNA (si-Con), si-RNA targeting all the NFI-X
isoforms (si-NFI-X) or si-RNA targeting specific splice isoform NFI-X3 (si-NFI-X3).
48hr post transfection RNA was isolated and subsequently the expression of YKL-40 was
measured and represented as % of control. RNA was isolated from stable pools of LN229
(C) or U373 (D) cells transfected with empty vector, NFI-X1 or NFI-X3 expression
plasmids, subsequently YKL-40 expression was measured by qPCR and normalized to
GAPDH expression as described in materials and methods. (E) YKL-40 protein
expression was detected in the conditioned media (CM) and the whole cell lysate (WCL)
of U373 cells overexpressing either empty vector, NFI-X1 or NFI-X3 by western
blotting. Tubulin was used as the loading control.
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3.4.3 YKL-40 controls migration and invasion of astrocytes and glioma cells. YKL40 has been shown to promote migration of vascular smooth muscle cells. Since high
expression of YKL-40 is associated with invasive GBM tumors [97], we explored
whether NFI-X3 controls migration and invasion of astrocytes and glioma cells via YKL40 dependent mechanism. The migration of primary astrocytes was reduced by 50%
when NFI-X was downregulated (Fig. 3.3 left panel). Conversely, migration of astrocytes
was markedly increased in response to exogenous YKL-40 (Fig. 3.3 right panel).
Subsequently, we analyzed migration and invasion of glioma cells overexpressing NFIX3. Overexpression of NFI-X3 induced migration of U373 cells by approximately 2.5
fold (Fig 3.4A left panel). Since YKL-40 expression was highly increased in U373-X3
cells (Fig. 3.2D), we asked whether YKL-40 was responsible for NFI-X3 induced
migration. Indeed, the down regulation of YKL-40 expression in U373-X3 cells
drastically reduced migration of these cells in wound healing assay (Fig. 3.4A right
panel) and trans-well migration assays (Fig. 3.4B left panel). Since YKL-40 is a secreted
protein we further explored its role in enhanced migration of glioma cells. For this
purpose, we collected the conditioned media of U373-X3 cells transfected with either
control (Si-Con) or YKL-40 (Si-YKL-40) siRNAs, added these media to U373-vec cells,
and analyzed the migration of these cells. Significantly, U373-vec cells migrated 2x more
slowly in the presence of medium of Si- YKL-40 treated than Si-con-treated cells (Fig.
3.4B right panel). These data indicate that NFI-X3 induced enhances glioma cell
migration via the induction of secreted YKL-40 expression.
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Figure 3.3

FI-X and YKL-40 control astrocyte migration. Astrocytes were

transfected with si-RNA to scrambled (con si) or to NFI-X (si-NFI-X) fourty-eight hours
post transfection, a scratch was made in the monolayer with a 2µl pipette tip. Cells were
allowed to migrate for 15 hours. Pictures were taken at 0hr and 15 hours after the scratch
was made (a). Astrocytes were plated to 95% confluency and grown overnight.
Subsequently, scratch was made, and cells were allowed to migrate in the presence of
media with or without purified YKL-40 (200ng/ml) for 15 hours. Pictures were taken as
described above (b). Number of cells migrated in to the wound were counted from six
random fields per experiments and represented as cells migrated per field.

87

88

Figure 3.4

FI-X3 and YKL-40 control glioma cell migration. Wound healing assay

was done in U373 cells expressing vec or NFI-X3 (left); or in U373-X3 transfected with
si-Con, or si-YKL-40, 30 hours post transfection scratch was made (right) and migrated
cells in the wound area were counted at the indicated time points (A). (B) Transwell
migration assay was done in U373-X3 cells with indicated si-RNA, number of cells
migrated were counted on fibronectin coated membrane (left); or in U373-vec cells,
migration was analyzed in the presence of CM from si-Con, or si-YKL-40 transfected
U373-X3 cells (right).
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Figure 3.5

FI-X3 and YKL-40 control glioma cell invasion. Matrigel invasion assay

was done with U373-vec or U373-X3 on boyden chamber slide (left), or with U373-X3
cells transfected with si-con or si-YKL-40 (right), cells were allowed for 8 hours to
invade through the matrigel. Number of cells invaded in the matrigel were counted from
six random fields per experiments and represented as cells invaded per field.
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Since YKL-40 has been shown to increase the in vitro invasion of transformed
astrocytes [153], we tested whether NFI-X3 and YKL-40 regulate glioma invasion.
Indeed,

cells

overexpressing

NFI-X3

were

twice

more

invasive

(Fig. 3.5 left panel), and siRNA to YKL-40 diminished their invasion by 40% (Fig. 3.5
right panel). Taken together, these data strongly suggest that YKL-40 controls migration
and invasion of astrocytes and glioma cells, respectively.

3.4.4 The expression of YKL-40 is induced by the cytokines of IL-6 family. Since
signaling through the JAK-STAT3 pathway is critical for astrocyte differentiation, and
IL-6 family cytokines activate JAK-STAT3 signaling, we sought to explore whether
YKL-40 is regulated by the JAK-STAT pathway. To this end, we stimulated astrocytes
with OSM and also IL-6 together with soluble IL-6 receptor (sIL-6R) (since astrocytes
express limited amount of IL-6R). Expression of YKL-40 mRNA was activated by 8-10
fold by OSM and 3 fold by IL-6/sIL-6R (Fig. 3.6A). OSM-stimulated YKL-40
expression was time-dependent (Fig. 3.6B) and was followed by the increased secretion
of YKL-40 into the medium (Fig. 3.6C).

3.4.5 STAT3 and

FI-X are critical for OSM-stimulated YKL-40 expression. To

identify which of the STATs control YKL-40 expression, we down-regulated the
expression of STAT1 and STAT3 which are known to be activated by OSM. Down
regulation of STAT3 alone or together with STAT1 reduced basal expression of YKL-40
by approximately 50% and almost completely abolished the OSM stimulation of YKL-40
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Figure 3.6 Effect of IL-6 family cytokine treatment on YKL-40 expression in

Ps

and Astrocytes. Astrocytes were stimulated with the indicated IL-6 family members for
24 hours. Then cells were trizol lysed and RNA was isolated subsequently YKL-40
expression was analyzed by qPCR (A). Astrocytes were stimulated with OSM for
indicated time points and YKL-40 expression was analyzed by qPCR (B). YKL-40
expression was normalized with GAPDH, and represented as fold change compared to
unstimulated cells. YKL-40 expression was detected by western blotting in CM and
WCL of astrocytes stimulated with OSM for 24 hour. Tubulin was used as loading
control (C).
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expression (Fig. 3.7). In contrast, STAT1 knock-down had no effect (Fig. 3.7). These
data suggest that STAT3, but not STAT1, controls OSM induced YKL-40 expression in
astrocytes.
Since NFI-X regulates basal expression of YKL-40 in astrocytes and glioma cells
(Fig. 2), we asked if it is also critical for the OSM-induced expression. We down regulated the expression of NFI-X and also all NFIs (pan-NFI) and analyzed the
expression of basal and OSM induced YKL-40 mRNA in astrocytes. Surprisingly, knockdown of NFIs or NFI-X diminished the basal and almost completely abolished the OSM
induced YKL-40 expression (Fig. 3.7), implying that NFI-X is a critical factor regulating
the expression of YKL-40 in astrocytes. In another approach we utilized our glioma cells
stably overexpressing NFI-X1 or NFI-X3 and measured YKL-40 expression upon OSM
treatment. Indeed, the expression of YKL-40 was induced by approximately 4-6 fold in
the cells overexpressing NFI-X1 or -X3, but not cells transfected with empty vector (Fig.
3.8). Collectively, these data clearly demonstrate that both STAT3 and NFI-X are
needed for OSM-induced YKL-40 expression in primary astrocytes.
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Figure 3.7 STAT3 and

FI-X are essential for OSM stimulated upregulation of

YKL-40 in astrocytes. Astrocytes were transfected with indicated si-RNA. 40 hours post
transfection cells were stimulated with OSM for 24 hours and subsequently YKL-40
expression was analyzed by qPCR. YKL-40 expression is represented as fold change
compared to unstimulated cells.
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Figure 3.8

FI-X1 and

FI-X3 isoform are critical for OSM stimulated YKL-40

expression in glioma cells. U373 and LN229 cells stably overexpressing either empty
vector, NFI-X1 or NFI-X3 were stimulated with OSM for 24 hours. Cells were lysed and
RNA was isolated subsequently YKL-40 expression was analyzed by qPCR. Target
expression was normalized with GAPDH and represented as fold induction compared to
unstimulated empty vector expressing cells.
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3.4.6 Identification of regulatory elements within the YKL-40 promoter critical for
its activation by OSM. To further characterize the mechanism of YKL-40 regulation by
STAT3 and NFI-X, the 1.3 kb upstream region of the human YKL-40 gene was screened
for the putative regulatory elements using MAT-INSPECTOR and TRANSFAC
programs (Fig. 3.9A) and one AP-1, two STAT, and four NFI binding elements were
identified. We obtained the -1.3kb YKL-40 promoter cloned in front of the luciferase
reporter gene (pYKL(-1300)-Luc) from Dr. Michael Rehli.
To assess the importance of STAT binding elements, we made mutants of each
STAT binding site in the pYKL(-1300)-Luc plasmid. Astrocytes were transfected with
either pYKL(-1300)-Luc or p-STATmut1-YKL-Luc or p-STATmut2-YKL-Luc and
stimulated with OSM. A moderate 3-fold induction in Luciferase reporter activity is
observed (Fig. 3.9A) upon OSM stimulation in the wild type reporter plasmid, suggesting
that OSM stimulated YKL-40 expression is due to the enhanced YKL-40 promoter
activity. As evident from the data, mutation in STAT binding site 1 dramatically reduced
the basal as well as OSM stimulated Luciferase reporter activity (Fig. 3.9A). However,
mutation of the STAT site 2 has no effect on reporter activity. These data implicate that
OSM stimulated YKL-40 reporter activity is mediated through STAT binding site 1
present within the YKL-40 proximal promoter.
To further validate the importance of STAT3 factor in OSM stimulated YKL-40
expression, we transfected primary astrocytes with pYKL(-1300)-Luc plasmid together
with plasmids expressing empty vector, constitutive active STAT3 (CA-STAT3) or
dominant negative STAT3 (DN-STAT3) and analyzed the Luciferase activity.
Interestingly, CA-STAT3 further enhanced the OSM stimulated reporter activity and had

101

no effect on basal YKL-40 reporter activity. Conversely, DN-STAT3 abolished the OSM
stimulated YKL-40 reporter activity and basal YKL-40 Luciferase activity was
unaffected (Fig. 3.9B).
Since OSM is known to transcriptionaly activate AP-1 family members [154] and
there is a single AP-1 binding element within the YKL-40 promoter, we sought to
explore the involvement of AP-1 element in OSM induced YKL-40 reporter activation.
To test this we made a mutation in the AP-1 binding element within the YKL-40 reporter
plasmid (p-mutAP-1-YKL-Luc), and transfected the mutant constructs into astrocytes.
Surprisingly, mutation in AP-1 binding element significantly reduced the OSM induced
YKL-40 reporter activity by 40%, and had no effect on basal reporter activity (Fig. 3.9A).
Moreover, a double mutant of STAT and AP-1 element (p-mutSTAT-AP-1-YKL-luc)
completely abolished the OSM induced YKL-40 reporter activity (Fig. 3.9A), suggesting
both STAT and AP-1 elements are necessary for OSM induced YKL-40 reporter activity.
To evaluate the effect of putative NFI binding elements, we made a deletion
mutant (p-delYKL-40-Luc) removing two of the putative NFI binding elements of YKL40 reporter, furthermore we utilized this deletion mutant plasmid to remove the 3rd NFI
binding element by mutagenesis (p-mut-NFI YKL-Luc). These plasmids were transfected
into astrocytes and luciferase activity is measured after OSM stimulation. Interestingly,
none of these mutant plasmids had any effect on either basal or OSM stimulated reporter
activity (Fig. 3.9A) ruling out the involvement of the NFI binding elements in YKL-40
promoter activation.
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Figure 3.9 STAT3 and AP-1 but not

FI elements are critical for OSM induced

YKL-40 reporter activity in astrocytes. Astrocytes were transfected with indicated
reporter plasmids as described in materials and methods and stimulated with OSM for 24
hours (A). Indicated expression plasmids were co-transfected with pYKL(-1300)Luc, 8
hours post transfection cells were stimulated with OSM for 24 hours (B). Luciferase
reading was measured and normalized by renilla reading. Data is represented as relative
Luciferase activity as fold change compared to pYKL(-1300)Luc control plasmid.
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Combining all these data we can conclude that STAT and AP-1 elements are
critical for YKL-40 reporter activation upon OSM treatment and that NFI elements do
not regulate YKL-40 promoter activation.

3.4.7 D A-Protein interaction studies to the YKL-40 regulatory elements
demonstrate the binding of STAT-3 and AP-1 family members:

From the reporter

analysis it is clear that STAT and AP-1 elements are needed for OSM stimulated YKL-40
promoter activation. Supershift assays showed STAT-3 as well as STAT-1 binding to the
YKL-40 promoter (Fig. 3.10A). Since, mutation of NFI elements showed no effect on
YKL-40 reporter activity and close analysis of YKL-40 promoter revealed a nonconsensus NFI element close to STAT element (Fig. 3.9A). Indeed, NFI and STAT
proteins are capable of binding, rather with low efficiency, to the NFI-STAT element as
demonstrated by competition with cold probe and antibody supershift assays (Fig.
3.10B). AP-1 family of transcription factors consists of c-Fos, Fos-B, Fra-1, Fra-2, c-Jun,
JunB, JunD etc. The obvious question we asked which of these members are involved in
the OSM regulated YKL-40 activation. The amount of DNA-protein complex is
enhanced at the AP-1 element of the YKL-40 promoter upon OSM stimulation (Fig
3.10C left panel). Moreover, supershift assays demonstrated the identity of AP-1
members, c-Fos, Fra-1, c-Jun and JunB bound to the corresponding AP-1 element (Fig
3.10C right panels). Interestingly, the binding of c-Fos was transient and could only be
observed at one hour of stimulation
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Figure 3.10 Binding of AP-1 complex to the putative binding element located at the
5` flanking region of the YKL-40 gene. Nuclear extracts from control astrocytes or
astrocytes stimulated with OSM for 4 hrs were analyzed by EMSA using oligonucleotide
corresponding to an AP-1 site (A). Supershift was performed using antibodies against cFos, Fos-B, Fra-1, Fra-2, c-Jun, Jun-B, Jun-D and non rabbit serum control nuclear
extract (NRS) (B) and 4hr OSM stimulated nuclear extract (C). Ten and 100 fold excess
of cold oligonucleotide competitors were added to the binding reaction as indicated.
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Figure 3.11 OSM stimulated YKL-40 expression does not depend on c-Fos, Fra-1
and c-Jun. Astrocytes were transfected with indicated si-RNA, and stimulated with OSM
for 20 hr or unless as indicated time for 1hr, 4hr or 20 hr and RNA was isolated and
subsequently the expression of YKL-40 (A-, B-left panels and C), c-Fos ( A-middle and
-right panels) and c-Jun (B right panel) was analyzed by qPCR. Data are normalized by
GAPDH expression and represented as fold change compared to unstimulated si-Con
cells.
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while other members were observed at both the stimulation time points one and four
hours (Fig. 3.10C).
It is well documented that OSM can stimulate c-Fos, Fra-1, c-Jun and JunB
expression in various cell types [155] [154]. In addition, NFI transcription factors are also
essential for PMA stimulated c- Fos expression [147]. We knocked-down the expression
of c-Fos, Fra-1, JunB and c-Jun using si-RNA in astrocytes and measured YKL-40
expression after stimulation with OSM. Surprisingly, none of the si-RNA showed any
effect on OSM induced YKL-40 expression, suggesting involvement of another member
(Fig. 3.11).

3.4.8 FI-X and STAT3 physically interact: Both NFI-X and STAT3 regulate YKL-40
expression (Fig. 2 and 5) and STAT and NFIs bind to the NFI-STAT element within
YKL-40 promoter (Fig. 3.10B). Therefore we sought to explore whether STAT3 may
directly recruit NFI-X to the YKL-40 promoter via direct STAT/NFI-X interaction. We
Immunoprecipitated NFI-X and found that STAT3 efficiently co-immunoprecipitated
from NFI-X3 and NFI-X1 cell lysates (Fig. 3.12A). Significantly, NFI-X3 interacted
more efficiently with STAT3 and OSM stimulation further increased this interaction (Fig.
3.12A). In another approach, we have cotransfected NFI-X1Flag or NFI-X3Flag
expressing constructs with STAT3-V5 palsmid and analyzed their interaction with
STAT3 in HEK cells. Indeed, NFI isoforms interacted with STAT3-V5 tagged protein
supporting our data from U373 cells. Interestingly, this interaction remained unaffected
after OSM stimulation (Fig. 3.12B) suggesting a cell type specific interaction.
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Figure 3.12

FI-X3 and STAT3 physically interact. (A) Co-immunoprecipitation was

performed from U373-Vec, -X1 or –X3 lysates using NFI antibody. Immunoprecipitated
samples were run on SDS-PAGE and STAT3 was detected in western blotting. Western
blotting for STAT3 and NFI was also done from total lysates (bottom panel). (B) HEK
cells were transfected with indicated plasmids. Post 24 hour transfection respective cells
were stimulated with OSM for 15 minutes and total cell lysates was prepared.
Subsequently, flag tagged protein was pull down by Flag beads followed by western blot
(WB) using V5 and NFI antibodies to detect STAT3-V5 and NFI-Flag proteins.

111

112

Thus, NFI-X and STAT3 physically interact and STAT3 may recruit and stabilize NFI-X
binding to the relatively poor NFI consensus site within the YKL-40 promoter. To our
knowledge this is the first report that NFI-X and STAT3 factors physically interact and
may control gene expression.
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3.5 DISCUSSIO
YKL-40 is a shared biomarker of inflammation and oncogenic transformation (*).
Accordingly, increased levels of YKL-40 can be detected in various CNS pathological
states associated with ongoing inflammation, including AD [103], MS and glioblastoma
[153]; however, the cells which express YKL-40 remains controversial. In fact, a recent
study demonstrated that YKL-40 is expressed by activated microglial cells in the SIVE
associated inflammation [102]. Nevertheless, YKL-40 expression in GBM cells, which
are of astrocytic origin, argues that YKL-40 may be expressed in astrocytes as well [153].
Here, we report that primary human astrocytes express and secrete YKL-40 (Fig. 2 A),
YKL-40 is also expressed during the differentiation of neural progenitor cells towards
astrocytes (Fig. 1 C), and YKL-40 expression is induced during postnatal mouse brain
development (Fig. 1 A, B). Interestingly, expression of YKL-40 during the postnatal
period P1 to P21 coincides with the differentiation and maturation of astrocytes in mouse
brain in vivo (E16 to P30) (19), suggesting that astrocytes may contribute to the induced
YKL-40 expression in the developing brain. Indeed, transcriptome analysis of the mouse
neurons, astrocytes and oligodendrocytes revealed that YKL-40 is expressed in astrocytes
from P1 to P30 [152].
Astrocyte differentiation is executed by several signaling pathways including,
JAK-STAT3, BMP-SMAD and Notch-Hes during embryonic mouse brain development
[17, 18, 105]. In vivo, IL-6 family cytokines including CT-1, LIF, IL-6 and OSM has
been shown to activate JAK-STAT3 pathway and subsequently induce astrocyte
differentiation [156]. In addition, recently a family of transcription factors called NFI has
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also been shown to control astrocyte differentiation. The family comprises of four
members NFI-A,-B,-C, and -X. More specifically, NFI-A and –B control early phase of
gliogenesis while, NFI-X and –C control marker gene expression during late phase of
astrocyte differentiation [18] [157]. Here we report that YKL-40 expression in astrocytes
is primarily regulated by NFI-X, to a lesser extent by NFI-C, but not by NFI-A or –B
(Fig. 2 A). Importantly, NFI-X3 (a splice isoform of NFI-X) seems to regulate YKL-40
expression since down-regulation of NFI-X3 in astrocytes and its overexpression in
glioma cells significantly affect YKL-40 expression (Fig. 2 B, C, D and E). In addition,
the expression of NFI-X3 precedes the expression of YKL-40 during astrocyte
differentiation (Fig. 1C and data not shown). Moreover, it is of interest, whether the
regulation of YKL-40 by NFI-X is astrocyte specific. Indeed, knock down of NFI-X and
NFI-C had no significant effect on the expression of YKL-40 in THP-1 monocytes,
suggesting cell type specific regulation (data not shown).
IL-6-type cytokines activate the expression of YKL-40 in astrocytes (Fig. 4) and
this activation depends on NFI-X and STAT3 (Fig. 5). STAT-3 binds to the STAT
binding element of YKL-40 promoter (Fig. 7C)) and this element is critical for OSM
induced activation (Fig. 6A). Since YKL-40 is induced during astrocyte differentiation
(Fig. 1C), it is not surprising that the NFI-X and STAT3, both important regulators of
gliogenesis, control YKL-40 expression. OSM efficiently activates JAK-STAT3 pathway
and receptor for OSM (OSMR) is expressed in neuroepithelial cells and differentiating
astrocytes [150]. Therefore, it is speculative that OSM activates astrocyte differentiation
and YKL-40 expression during embryonic brain development.
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Although NFI-X regulates YKL-40 expression (Fig. 2 and 5), and there are three
putative NFI binding elements within the -1.3 kb YKL-40 promoter, deletion and
mutation to these NFI binding sites had no effect on the YKL-40 reporter activity (Fig.
6A). These data rule out the possibility of direct binding of NFI-X to these regulatory
elements. NFI-X may also bind to the elements located outside of the -1.3kb long
promoter. However, our data suggests that NFI-X is indirectly recruited to the YKL-40
promoter by STAT3 that binds to the proximal STAT element. This is strongly supported
by the following observations: both NFI and STAT3 weakly bind to the oligonucleotide
harboring both NFI and STAT elements in vitro (Fig. 7C); also STAT3 and NFI-X are
found in a complex (Fig. 8A and B). Interestingly, the interaction of STAT3 with NFI-X3
is stronger than NFI-X1, which lacks proline rich transcriptional activation (TA) domain
(Fig. 8A). Since, proline rich domains are often involved in protein: protein interactions
[158], it is possible that in part, NFI-X3 interacts with STAT3 via its TA domain. It
remains to be explored whether a NFI-X/ STAT3 complex controls a specific subset of
the astrocyte-specific genes during the differentiation. Significantly, a specific subset of
genes regulated by the STAT3:NF-κB complexes have recently been shown to differ
from genes regulated by STAT3 [159]. Since STAT3 is ubiquitously expressed and
controls a wide variety of cell functions, it is proposed that its interactions with other
transcription factors provide tissue specific functions [159].
NFI-X3 controls astrocyte and glioma cell migration and invasion via regulating
expression of YKL-40 (Fig. 3B, C, and D). In addition, exogenous YKL-40 controls
astrocyte migration (Fig 3A right panel). These data support previous findings that
transformed astrocytes overexpressing YKL-40 are more invasive [153]. Moreover, NFI-
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X knock-out mice show defects in migration of the subventricular zone progenitor cells
[119]. Similar to NFI-X, NFI-A and –B control tangential neuronal migration by
regulating the expression of ephrin-B1, and N-cadherin which are cell adhesion
molecules [160]. Thus, different NFIs likely regulate different target genes to affect cell
migration.
In conclusion, we propose that NFI-X and STAT3 control the migration of
differentiating astrocytes as well as migration and invasion of glioma cells via regulating
YKL-40 expression.
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CHAPTER: 4
SUPPLEME TARY OBSERVATIO S

4.1 I TRODUCTIO
High serum level of YKL-40 is associated with wide variety of inflammatory
conditions including encephalitis, meningitis, asthma, rheumatoid arthritis, and
sarcoidosis. Noteworthy, YKL-40 is rarely observed in the serum of healthy individuals
Therefore, it is regarded as one of the prominent markers of inflammatory conditions
which is mainly expressed by differentiated macrophages, and neutrophils [91].
According to the predicted role of YKl-40 in inflammation, YKL-40 knock out mice
show diminished antigen-induced Th2 responses partly due to the lack of IL-13-induced
tissue inflammation, and alternative macrophage activation [94]. High levels of YKL-40
were observed in several neurological disorders, including Alzheimer’s disease,
Parkinson’s disease, Multiple sclerosis, and Schizophrenia [97, 103, 104]. These
pathologies are associated with the ongoing CNS inflammation, suggesting that YKL-40
may play some important but yet to be identified role in these CNS pathologies.
Interestingly, microglia and astrocytes are the major modulators of inflammatory
responses, which produce various cytokines, chemokines and neurotrophic factors. In
fact, alternatively activated microglia were accounted for the elevated levels of YKL-40
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in AD patients [103]. Nevertheless, astrocytes become reactive in response to
inflammation or injury and also can be a source of YKL-40 (chapter 3).

4.2 RESULTS
4.2.1 Pro-inflammatory cytokines stimulate YKL-40 expression in astrocytes: The
regulation of YKL-40 expression in reactive astrocytes has not been explored to date.
Since

astrocytes

produce

YKL-40,

we

tested

whether

a

combination

of

neuroinflammatory cytokines, including IL-6, OSM, and IL-1 regulate YKL-40
expression. Indeed, YKL-40 expression was activated by IL-1 or IL-6+sIL-6r and OSM
(6-10 fold), but was synergistically enhanced by combination of IL-1 and OSM (200-300
folds) and IL-1 and IL-6+sIL-6r (50 folds) (Fig. 4.1).

4.2.2 Astrocytes but not microglia respond and secret YKL-40 in response to
cytokines: In order to compare regulation of YKL-40 expression in microglia with its
regulation in astrocytes, we stimulated rat primary microglial cells with IL-1, IL-6/sIL6R, and TNFα. We also used LPS (Lipo-polysaccharide) as the positive control for
microglial activation. Moreover, none of these cytokines were able to enhance YKL-40
expression or induce its secretion (Fig. 4.2 right panel). Since microglia do not express
receptors for IL-1, TNF, IL-6 they were not able to respond. Surprisingly, LPS a strong
activator of microglia also failed to activate YKL-40 expression and secretion in these
cells. These data suggest that YKL-40 is regulated both at the level of its transcription
and protein secretion in a cell specific manner. This is supported by the findings that
astrocytes respond to cytokine stimulation and induce YKL-40 expression as well as
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secretion (Fig 4.2 left panel). However, microglia are insensitive to cytokine stimulation
in terms of YKL-40 expression and secretion. As a result of these observations we
propose that activated astrocytes are primary source of YKL-40 in CNS pathologies.
Figure 4.1 Effect of pro-inflammatory cytokine on the YKL-40 expression in
Astrocytes. Astrocytes were stimulated with the indicated cytokines for 24 hours. Then
cells were trizol lysed and RNA was isolated. Subsequently YKL-40 expression was
analyzed by qPCR. YKL-40 expression was normalized with GAPDH, and represented
as fold change compared to unstimulated cells.
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Figure 4.2. Comparison of YKL-40 expression between astrocytes and microglia.
Primary human astrocytes and Primary rat microglia (derived from postnatal rat brain day
3 P-3) were grown overnight in serum free media followed by stimulation with the
indicated cytokines for 24 hours. Conditioned media was collected and cells were lysed
in denaturing cell lysis buffer. Conditioned media was concentrated ten times and run on
SDS-PAGE with the total cell lysates. Subsequently YKL-40 expression was analyzed by
western blotting. Tubulin is used as loading control.
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4.2.3

YKL-40

inhibits

Myelin

basic

protein

(MBP)

expression

during

oligodendrocyte differentiation in vitro. Since YKL-40 is a secreted molecule, it may
interact with and affect functions of other cell types in a paracrine manner. Indeed, a
recent study has demonstrated that YKL-40 inhibits bFGF-induced dendrite formation in
hippocampal neurons [102]. In preliminary experiments we found that YKL-40 inhibits
myelin basic protein (MBP) gene expression during the differentiation of oligodendrocyte
progenitor cells (OPCs) (Fig. 4.3).
These data are of great interest considering that high levels of YKL-40 are found
in MS [104]. Thus, YKL-40 could be one of the molecules produced by reactive
astrocytes, which may contribute to the MS pathology. However, the exact role of YKL40 in oligodendrocyte differentiation and myelin production remains to be studied in the
future.
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Figure 4.3. Effect of purified YKL-40 on rat oligodendrocyte progenitor cell
differentiation. Oligodendrocyte progenitor cells (OPCs) were isolated from rat brain
(postnatal day three) and cultured and differentiated for 4 days in a defined media.
Purified YKL-40 was added every alternate day directly to the OPC differentiation media
at the indicated concentrations. At the end of differentiation cells were lysed in lysis
buffer followed western blotting for myelin basic protein, CNPase, and actin proteins.
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CHAPTER 5
GE ERAL DISCUSSIO A D FUTURE DIRECTIO S

Astrocytes are the most abundant cells in the CNS, and regulate normal as well as
disease associated functions of neurons. A lot of attention has been focused on the
understanding of their differentiation, development and function. Indeed, a number of
signaling pathways, including JAK-STAT, BMP-SMAD and Notch, control their
differentiation from precursor cells. Recently, NFI family of transcription factors has also
been shown to control gliogenesis [105].
NFI family consists of four members including, NFI-A, -B, -C and –X. All NFIs
share a conserved DNA binding domain, and has a variable transactivation domain. Like
many other transcription factors these can either activate or repress genes in a promoter
and tissue specific manner. Furthermore, these are expressed in various tissues in an
overlapping and complex pattern, suggesting their importance during tissue development
[22]. The expression of NFI-A, -B, and -X was observed in developing neocortex of
mouse brain, implying their importance in the brain development [27].
The functions of NFI-A are well documented in the control of gliogenesis. In
chick embryo spinal cord, NFI-A and NFI-B has been shown to control the astrocyte
differentiation [18]. Accordingly, NFI-A knock out animals display phenotype with the
loss of midline glial population, and a lack of GFAP expression. In addition, NFI-A and
NFI-B deficient animals show a defect in the crebellar granule neuron migration [160].
Before the onset of gliogenesis astrocyte specific genes are methylated and not expressed.
In fact, demethylation of the astrocyte specific promoters is one of the critical and early
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events for gliogenesis to occur. Recently an elegant study demonstrated that NFI-A factor
is critical for the demethylation of promoters during the gliogenesis. However, the exact
mechanism of this regulation and role of other NFI factors during astrocyte
differentiation is not clear [25].
NFI-X is also expressed within the developing and adult mouse brain.
Accordingly, animals lacking Nfix gene showed impaired brain development with loss of
partial

corpus

callosum,

hydrocephalus

and

defect

in

progenitor

cell

migration/differentiation. Furthermore, these animals died postnataly and can survive
only when fed on a soft chow diet [119]. These studies clearly indicated the importance
of NFI-X in the brain development. Indeed, we have previously shown that NFI-X is
expressed during the differentiating astrocytes from human neural progenitors and control
late astrocyte marker gene expression, including GFAP and SPARCL-1[23].
Alternative splicing is a common mechanism to generate many proteins with
varied function from a same transcript. NFIs also undergo alternative splicing, generating
as many as 9 splice variants for each gene [26]. There are several splice variants, either
computer predicted or cloned, of Nfix transcripts. Most likely, these splice isoforms carry
different functions depending on their protein sequence and structure. Nonetheless, the
documented NFI-X splice isoforms has been cloned either from mouse or from Xenopus
[116, 136]. However, the expression and function of NFI-X splice isoforms from human
CNS cells remained unexplored.
In this dissertation, we have analyzed the expression and function of NFI-X splice
isoforms in primary human astrocytes. A novel human isoform NFI-X3 is cloned and
characterized. NFI-X3 is unique due to the insertion of exon 9 causing a frame shift in
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protein sequence and subsequent generation of proline rich C-terminal transactivation
domain (chapter 2). Surprisingly, this unique proline rich transactivation domain is
almost 100% conserved among higher mammals and contains more prolines compared to
the Xenopus NFI-X3 lacking a strong trans-activation potential. Further suggesting that
NFI-X3 isoform might have acquired additional and unique functions during the
evolution of higher animals. Indeed, NFI-X3 strongly activates the expression of several
genes including, GFAP and, SPARCL-1 compared to NFI-X1 (lacking proline rich
transactivation domain) (chapter 2). Moreover, its expression increases during the invitro
astrocyte differentiation and precedes the expression of GFAP and SPARCL-1
suggesting, NFI-X3 is an important regulator of marker gene expression during astrocyte
differentiation.
NFI factors regulate gene expression via different mechanisms including, direct
binding to its consensus DNA binding element, interaction with various transcription
factors, and competition with the Sp1 for the binding on adjacent DNA binding elements.
In another study, NFI-C has been shown to interact with RNA-PolII and may recruit
transcription initiation machinery to the gene promoters. In addition, these factors may
interact with histone H3 as part of their mechanism of gene activation [26]. Recently,
NFI-A has been shown to play a critical role in the demethylation of the astrocyte
specific genes subsequent activation [25]. Astrocyte specific gene expression also
depends on the histone-acetylation on specific lysine residues (H3K4) during gliogenesis.
However, NFI-X3 has no significant effect on methylation of CpG sites within GFAP
promoter (chapter 2). Chromatin immunoprecipitation revealed no significant changes in
the H3K4 acetylation levels of GFAP promoter. Moreover, NFI-X3 expressing cells
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showed two fold enhanced recruitment of RNA-PolII on the GFAP promoter. However,
the precise mechanism of RNA-PolII recruitment by NFI-X3 remained a quest for future
work. Direct interaction between RNA-PolII and NFI-X1 or NFI-X3 was similar (data
not shown), excluding the possibility of RNA-PolII recruitment via NFI-X3-RNA-PolII
interaction. Since, NFI-C can interact with and bring BRG-1 (a subunit of the chromatin
remodeling complex) to remodel the promoters [161], we explored the possibility of
interaction between NFI-X3 and BRG-1. However, we could not detect interaction
between these proteins in Co-IP experiments, suggesting BRG-1 independent regulation.
However, an attempt to map the nucleosome position at the TSS of GFAP gene revealed
no apparent changes in their location. However, possibility of nucleosome remodeling by
NFI-X3 on GFAP transcription start site can not be excluded.
NFIs are critical for normal mouse brain development, and NFI-X is a critical
regulator of astrocyte marker genes during their differentiation [26, 118]. However, the
downstream genes regulated by NFIs remained elusive. Microarray analysis performed
on our NFI-X3 isoform expressing glioma cells identified changes in the expression of
several genes (data not shown). Interestingly, most of the highly upregulated genes
encode proteins associated with extracellular matrix (ECM) including, SPARCL-1, YKL40, Periostin, TIMP-3, MMP-3, and Thrombospondin 3 (TSP3).
ECM plays a critical role in maintaining the tissue homeostasis, and particularly
during the embryo development, when cells generated from the precursors, in a relatively
small compartmentalized area, has to migrate out to the distant but proper locations.
Similarly, SPARCL-1 has been shown to be expressed by radial glia in the embryonic
CNS and regulate radial glial guided neuronal migration[162]. In addition, SPARCL-1 is
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expressed in the astrocytic processes ensheathing synaptic connections suggesting its role
in synapse remodeling [163]. Indeed, unpublished work from Dr. Cagla Eroglu group has
demonstrated a synaptogenic function for SPARCL-1[163]. Considering the abnormal
brain development in the NFI-X knock out animals, it is tempting to analyze the
SPARCL-1 expression and the synaptic structures in these animals. Similarly, a plethora
of functions are associated with THBS, including angiogenesis, cell migration, and
proliferation. Interestingly, all the THBS are expressed by astrocytes during early CNS
development and control synapse formation [4]. Furthermore, THBS-3 is upregulated in
reactive astrocytes after injury and may help repair synapse formation [78]. TIMP-3 is
another ECM protein, and controls congintive functions in mice [164]. In addition,
TIMP-3 is also upregulated in AD and may contribute to the processing of amyloid beta
peptide [165]. Taken together, ECM proteins play critical role in normal and pathological
CNS functions. Since, expression and function of YKL-40 in normal brain remained
unexplored, we sought to address its expression, regulation and function in the CNS cells.
YKL-40 also known as CHI3L1 is a secreted ECM protein and is highly
upregulated in malignant glioblastoma (GBM) [97]. Moreover, its high expression is
correlated with the invasive GBM tumors and poor prognosis of the patients [166].
Accordingly, transformed human astrocytes overexpressing YKL-40 are highly invasive
and resistant to radiation, suggesting YKL-40 to be a pro-oncogenic factor [153]. In non
CNS tissue, it is highly expressed during differentiating macrophages from monocytes
[92]. It is also expressed during the early development of human musculoskeletal system
[167]. However, its expression and function in developing CNS cells remained elusive.
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Here, we provide the evidence for the first time that, YKL-40 is expressed in the
early postnatal mouse brain developmental period P1 to P21 (Chapter 3). We further
demonstrate that its expression is increased during astrocyte differentiation in vitro,
suggesting YKL-40 is produced by astrocytes in the developing brain. Astrocytes can be
categorized into two major classes based on their location and function within the CNS
in-vivo. It will be important to establish its expression in the sections of brain in vivo
using immunohistochemistry, as to what type of regional astrocytes produce YKL-40. It
is also important to analyze its expression and function in the adult brain.
Furthermore, we validated the microarray data of increased YKL-40 expression in
U373-X3 cells by Q-PCR (chapter 3). Moreover, knockdown of NFI-X3 and NFI-X
reduced the YKL-40 expression in primary astrocytes. In addition, we also show that
STAT-3, another factor involved in astrocyte differentiation, controls basal expression of
YKL-40 in astrocytes. These data indicate that YKL-40 may be an astrocyte specific
factor in CNS whose expression is controlled by gliogenic transcription factors NFI-X
and STAT-3. Nevertheless, individual knock down of NFI-A, -B, -C, and –X
demonstrated that YKL-40 is specifically controlled by NFI-X and to a lesser extent by
NFI-C (data not shown). It remains interesting to analyze YKL-40 expression in
individual NFI knock-out animals.
We also stimulated primary astrocytes with cytokines of IL-6 family (IL-6 and
OSM), which both activates JAK-STAT pathway, and show that YKL-40 expression is
induced. Furthermore, this induced expression is controlled by STAT3 (but not STAT1)
and to our surprise by NFI-X. Detailed analysis of reporter activity suggested
indispensable role of STAT and AP-1 elements in the basal and OSM induced YKL-40
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promoter activation. Interestingly, mutations in the putative NFI binding elements of
YKL-40 promoter had no significant effect on basal or OSM induced reporter activity.
This led us to hypothesize that NFI-X could be recruited by STAT3 on a NFI nonconsensus site adjacent to STAT site in the YKL-40 promoter.
Indeed, we were able to detect STAT3 and STAT1 (data not shown) in NFI-X
Co-IP experiments. Furthermore, the interaction of STAT3/STAT1 with NFI-X3 was
significantly more and this interaction was further enhanced after OSM stimulation
(chapter 3). Whether, this interaction is physiologically relevant and occurs on YKL-40
promoter will be analyzed in detail in future. Similarly, previous studies has
demonstrated interaction between STAT3 and NF-κB which controls a different subset of
genes than by STAT3 [159]. In the same study it was also proposed that STAT3 may
regulate different subsets of genes by interacting with other transcription factor (s). Since,
NFI and STAT3 both are critical for astrocyte differentiation; it is possible that other
astrocyte specific genes may also be regulated by this interaction. It remains open for
future studies to analyze if the interaction between NFI-X and STAT3 is specific or other
NFIs (-A, -B, and -C) can also interact with other STAT family members or vice-versa.
The domains involved in this interaction will also be analyzed.
YKL-40 has been shown to control the migration and adhesion of endothelial
cells [91]. Here, we demonstrate that YKL-40 controls migration of primary astrocytes in
vitro. Furthermore, NFI-X also controls astrocyte migration likely via regulating YKL-40
expression (chapter 3). Indeed, NFI-X3 overexpressing glioma cells migrate and invade
with greater efficiency, and this effect was abolished when YKL-40 expression was
knockdown. Thus NFI-X controls glioma cell migration and invasion in vitro by
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regulating YKL-40 expression. Taken together, we would like to propose that YKL-40
controls astrocyte migration during CNS development, and this normal function of YKL40 is utilized by glioma cells (harboring constitutively active STAT3) with elevated
levels of YKL-40 for their invasive phenotype.
Elevated levels of YKL-40 can be identified in micro-array/ proteome analysis of
most of the CNS pathologies including AD, PD, MS and GBM. We have demonstrated
that pro-inflammatory cytokines IL-1, IL-6 and OSM can induce YKL-40 expression in
primary human astrocytes, and this induction was further synergistically activated by
these cytokines when added in combination (chapter 4). Conversely, microglia are
irresponsive to cytokine stimulation for YKL-40 expression (chapter 4). Surprisingly,
YKL-40 was detected in whole cell lysates (WCL) but not in the conditioned media (CM)
of microglia (in contrast to astrocytes, where YKL-40 is detected in CM but not in WCL)
suggesting cell type specific regulation of YKL-40 expression and secretion. This data
clearly suggests that astrocytes are one of the sources for increased YKL-40 levels in
CNS pathologies. However, the regulation and role of YKL-40 in reactive astrocytes
remains to be worked on in future. Nevertheless, our data that YKL-40 controls astrocyte
migration strongly suggests that elevated levels of YKL-40 in reactive astrocytes may
help them migrate in response to an injury. We have also demonstrated that purified
YKL-40 inhibits MBP expression during oligodendrocytes differentiation from OPCs
(chapter 4). Indeed, recently a very elegant study has identified high levels of CSF- YKL40 in association with conversion to MS [104]. Since YKL-40 is an anti-apoptotic, prosurvival and pro-migratory/ chemo-attractant factor, it is speculative that high YKL-40
levels at the sites of MS lesions (produced by reactive astrocytes) might attract OPCs but
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simultaneously inhibit their maturation in order to re-myelinate the injured axons.
However, the precise role of YKL-40 on oligodendrocytes/OPC differentiation remains
to be elucidated in future studies. In conclusion, YKL-40 could be a very interesting drug
target for the treatment of MS.
Based on these data we would like to propose regulation and role of YKL-40
during CNS inflammation as shown below.

Endogenous ligand

(CNS resident macrophage)
YKL-40 ??Macrophage)
?

YKL-40 ???

Neuron/ Oligodendrocyte de-myelination

In conclusion, this dissertation has identified NFI-X3, a novel splice isoform of
NFI-X, as the major regulator of astrocyte marker genes by a novel mechanism likely via
135

nucleosome remodeling/eviction. In addition, NFI-X also controls astrocyte migration
and glioma cell invasion by regulating the expression of YKL-40, a novel astrocyte
differentiation associated secreted molecule. YKL-40 expression is also regulated by
STAT3 another gliogenic factor. We also expand the knowledge of mechanisms of OSM
induced YKL-40 expression in glioma (tumors). Based on the findings in this
dissertation, we can draw a model of YKL-40 expression and its hypothetical functions in
normal and pathology associated CNS.

, LIF,
IL-6, OSM
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